Committee on Energy and Commerce U.S. House of Representatives · Committee on Energy and Commerce U.S. House of Representatives Witness Disclosure Requirement - "Truth in Testimony"

Committee on Energy and Commerce U.S. House of Representatives

Witness Disclosure Requirement - "Truth in Testimony" Required by House Rule XI, Clause 2(g)(5)

1. Your Name: GEORGE A. WILLIAMS, MD

2. Your Title: PRESIDENT ELECT, AMERICAN ACADEMY OF OPHTHALMOLOGY

3. The Entity(ies) You are Representing: AMERICAN ACADEMY OF OPHTHALMOLOGY

4. Are you testifying on behalf of the Federal, or a State or local government entity?

Yes

No X

5. Please list any Federal grants or contracts, or contracts or payments originating with a foreign government, that you or the entity(ies) you represent have received on or after January 1, 2015. Only grants, contracts, or payments related to the subject matter of the hearing must be listed.

NONE 6. Please attach your curriculum vitae to your completed disclosure form.

Attached.

Signature: Date: 1/25/2018

INSTRUCTIONS FOR COMPLETING THE TRUTH-IN-TESTIMONY DISCLOSURE FORM

George A. Williams, MD, is Chair, Department of Ophthalmology and Director of the Beaumont Eye Institute at Beaumont Health in Royal Oak, Michigan. He is Professor and Chair of Ophthalmology at Oakland University William Beaumont School of Medicine and a partner with Associated Retinal Consultants. He is Professor at the European School for Advanced Studies in Ophthalmology in Lugano, Switzerland. An Alpha Omega Alpha graduate of Northwestern University Feinberg School of Medicine, Dr. Williams completed his residency in ophthalmology and his fellowship in vitreoretinal surgery at the Eye Institute of the Medical College of Wisconsin where he was an associate professor until 1988. Dr. Williams has published more than 250 articles and book chapters in the field of vitreoretinal surgery. He has participated as principal investigator or co-investigator in more than 20 clinical trials sponsored by the National Eye Institute and industry. He served on the Board of Trustees of the American Academy of Ophthalmology (AAO) from 2008 to 2012. He is a recipient of the Special Recognition Award, the Secretariat Award and the Lifetime Achievement Award of the AAO. He has delivered 26 named lectureships, including the 2013 Gertrude Pyron Lecture at the American Society of Retina Specialists (ASRS), the 2014 Yasuo Tano, MD, Lecture at the Club Jules Gonin, the 2015 Taylor Smith, MD Lecture at the Aspen Retinal Detachment Society and the 2017 B. Thomas Hutchinson, MD Lecture at the New England Ophthalmology Society. He is a recipient of the ASRS Crystal Apple Award for teaching excellence and has trained over 100 clinical and research vitreoretinal fellows. Dr. Williams is past chair of the AAO Retina Ophthalmic Technology Assessment Committee. He was Secretary for Federal Affairs from 2014 through 2017. On January 1, 2018, he became AAO President-elect. Since 2006, he has represented the AAO at the Relative Value Update Committee (RUC) of the American Medical Association. He is past president of the ASRS and the Michigan Society of Eye Physicians and Surgeons. He is Chair of the Board of Directors of the Ophthalmic Mutual Insurance Company. He is an Associate Editor for Surgical Techniques for the journal RETINA, and serves on the editorial boards of Retinal Cases & Brief Reports and Current Opinion in Ophthalmology. Dr. Williams is a recertified Diplomate (2005, 2016) of the American Board of Ophthalmology and a member of the Retina Society, Macula Society, ASRS, Association of University Professors in Ophthalmology and Club Jules Gonin. He is an elected Fellow of the Association for Research in Vision and Ophthalmology.

Updated 12/17

UPDATED: January 23, 2018 NAME: George A. Williams, M.D. WORK ADDRESS: Beaumont Eye Institute

3535 West Thirteen Mile Road #555 Royal Oak, Michigan 48073

Associated Retinal Consultants, P.C. 3555 West Thirteen Mile Road, Suite LL-20 Royal Oak, Michigan 48073-6710

OFFICE PHONE:

EMAIL ADDRESS

CITIZENSHIP: United States EDUCATION:

1970-1974 Denison University, B.A. Granville, Ohio

1974-1978 Northwestern University, M.D. Chicago, Illinois

INTERNSHIP:

1978-1979 Blodgett Memorial Medical Center Grand Rapids, Michigan

RESIDENCY:

1979-1982 Ophthalmology Eye Institute, Medical College of Wisconsin R.O. Schultz, M.D., Director Milwaukee, WI

1981-1982 Chief Resident, Eye Institute, Medical College of Wisconsin FELLOWSHIPS:

1982-1983 National Research Service Award Physiology and Biochemistry of the Eye Eye Institute, Medical College of Wisconsin H.F. Edelhauser, Ph.D., Director

CURRICULUM VITAE

George A. Williams, M.D. Page 2 1983-1984 Diseases and Surgery of the Retina and Vitreous Eye Institute, Medical College of Wisconsin T.M. Aaberg, Sr., M.D., Director MEDICAL LICENSE: Michigan BOARD CERTIFIED: National Board of Medical Examiners, Diplomat - 1979 American Board of Ophthalmology, Fellow – 1983 Recertified 1/1/2005 through 12/31/2015 Recertified 1/1/2016 through 12/21/2025 HOSPITAL APPOINTMENTS: Beaumont Hospitals Royal Oak, Michigan ACADEMIC APPOINTMENTS: May, 2009 – Present Chair, Department of Ophthalmology Oakland University William Beaumont School of Medicine Rochester, Michigan Professor of Ophthalmology and Biomedical Sciences Oakland University William Beaumont School of Medicine Rochester, Michigan March, 2008 – Present Professor European School for Advanced Studies in Ophthalmology Lugano, Switzerland June 1, 2007-January 1, 2017 Vice-Chief, Surgical Services, Academic Affairs Beaumont Hospitals March 7, 2001- Present Chair, Department of Ophthalmology Director, Beaumont Eye Institute Beaumont Hospitals Royal Oak, Michigan November 1, 2000-March, 2001 Interim Chair, Department of Ophthalmology Director, Beaumont Eye Institute William Beaumont Hospital Royal Oak, Michigan 1992-2001 Chief of Vitreoretinal Surgery Director of the Vitreoretinal Fellowship Beaumont Eye Institute William Beaumont Hospital Royal Oak, Michigan 1999- Present Clinical Professor of Biomedical Sciences Eye Research Institute Oakland University Rochester, Michigan 1990-1999 Clinical Associate Professor of Biomedical Sciences Eye Research Institute

George A. Williams, M.D. Page 3 Oakland University Rochester, Michigan 1989-1992 Associate Clinical Professor Department of Ophthalmology Wayne State University Kresge Eye Institute Detroit, Michigan July, 1988-August, 1988 Associate Professor Department of Ophthalmology Medical College of Wisconsin Milwaukee, Wisconsin

July, 1984 - June, 1988 Assistant Professor Department of Ophthalmology Medical College of Wisconsin Milwaukee, Wisconsin 1979-1984 Assistant Instructor Medical College of Wisconsin Milwaukee, Wisconsin 1983-1986 Attending Physician Veteran's Administration Wood, Wisconsin

NATIONAL COMMITTEES: 2018 – 2019 President Elect, American Academy of Ophthalmology 2014 – 2017 Secretary, Federal Affairs, American Academy of Ophthalmology 2017 – 2019 Vice Chair, Relativity Assessment Workgroup, RUC/AMA 2016 – 2019 Chairman of the Board, Ophthalmic Mutual Insurance Company (OMIC) 2015 – 2017 Chair, Surgical Global Workgroup RUC/AMA 2014 – 2016 Chair, Multispecialty Point of Comparison, RUC/AMA 2013 Leadership Council Member, American Academy of Ophthalmology 2012 Executive Committee, American Academy of Ophthalmology 2012 – 2014 Research Subcommittee RUC/American Medical Association 2011 Nomination Committee, American Academy of Ophthalmology 2009 – 2012 Board of Trustees, American Academy of Ophthalmology 2009 – 2012 Membership Advisory Committee, American Academy of Ophthalmology 2009 – 2012 Audit Committee, American Academy of Ophthalmology 2009 – Present American Academy of Ophthalmology Delegate to the AMA Specialty Society RVS Update Committee (RUC) 2009 – 2012 Relativity Assessment Workgroup, RUC/AMA 2009 – 2012 Administrative Committee, RUC/AMA 2004 – 2016 Chair, Awards Committee, American Society of Retina Specialists 2010 – 2012 Retina Research Foundation Award of Merit & Gass Award Committee, Retina Society 2011– 2013 Delegate on the Board of Directors, Pan-American Association of Ophthalmology (PAAO) 2006 - 2009 American Academy of Ophthalmology Alternate delegate to the AMA Specialty Society RVS Update Committee (RUC) 2007-2008 American Academy of Ophthalmology, Revitalization Study Group 2001-2006 Emeritus Director, Member Executive Committee, American Society of Retina Specialists

George A. Williams, M.D. Page 4 2000-2001 Chair, Program Committee, Retina 2001, Pre-Academy Meeting, American Academy of Ophthalmology 2001-2005 Chairman, Ophthalmic Technology Assessment Committee (OTAC Retina Panel), American Academy of Ophthalmology American Academy of Ophthalmology 2000-Present Federal Health Policy Committee American Academy of Ophthalmology 2000 Co-Chair, Program Committee, Retina 2000, Pre-Academy Meeting American Academy of Ophthalmology 1996-2000 Committee on Ophthalmic Procedure Assessment, Retina Panel American Academy of Ophthalmology

HOSPITAL/SCHOOL OF MEDICINE COMMITTEES: 2017 Co-Chair, Search committee for chief of Surgical Services, Beaumont Health 2017 Member, Perioperative Executive Committee 2016 Chair, Search Committee for Chair of Pathology, Beaumont Health. 2015 - Present Chair, Committee on Appointment, Promotion and Tenure, Oakland University

William Beaumont School of Medicine 2012 Chair, Surgical Services, Health System Chair Search Committee 2011 – 2012 Self Study Committee, Oakland University William Beaumont School of Medicine 2009 – 2010 Constitutional Bylaws Committee, Oakland University

William Beaumont School of Medicine 2009 – 2014 Vice Chair, Committee on Appointment, Promotion and Tenure, Oakland University

William Beaumont School of Medicine 2007 – 2017 Surgical Executive Council 2001 – Present Medical Executive Committee 2008-2009 Curriculum Committee, Oakland University William Beaumont School of Medicine 2008 Co-Chair, Screening/Search Committee for Founding Dean of Oakland University William Beaumont School of Medicine 2005 Chair, Search Committee for Medical Director of Beaumont Research Institute MEMBERSHIPS: American Academy of Ophthalmology Association for Research in Vision and Ophthalmology Michigan Society of Eye Physicians and Surgeons Macula Society Retina Society Vitreous Society (1984-2002) American Society of Retina Specialists (2002-present) Club Jules Gonin Pan American Association of Ophthalmology Milwaukee Ophthalmological Society, 1984-1988 American Association for the Advancement of Science Oakland County Medical Society American Medical Association Detroit Ophthalmological Club Michigan State Medical Society AWARDS: Alpha Omega Alpha Phi Beta Kappa

George A. Williams, M.D. Page 5

Omicron Delta Kappa Honor Award, American Academy of Ophthalmology, 1991 Honor Award, The Vitreous Society, 1997 Senior Achievement Award, American Academy of Ophthalmology, 2001 Senior Honor Award, The Vitreous Society, 2001 Secretariat Award, American Academy of Ophthalmology, 2005 Secretariat Award, American Academy of Ophthalmology, 2007 Special Recognition Award, American Academy of Ophthalmology, 2007 Ophthalmology Lifetime Achievement Award for Vitreoretinal Excellence 3rd Mediterranean Retina Meeting, Istanbul, 2008

Fellow, Association for Research in Vision and Ophthalmology (ARVO), 2009 Outstanding Academic Excellence Award, “The Triple Threat” William Beaumont Hospital, 2010 Life Achievement Honor Award, American Academy of Ophthalmology, 2011 Gertrude D. Pyron Award, American Society of Retina Specialists, 2013 America’s Top Doctors, 1992-2017, Charter Member

Best Doctors in America, 1992-2017 VISITING PROFESSORSHIPS: October, 1985 University of Texas Medical Board Galveston, TX March, 1987 University of Texas Medical Board Galveston, TX March, 1988 Kuwait University School of Medicine Kuwait September, 1989 Harvard University Massachusetts Eye and Ear Infirmary Cambridge, MA October, 1989 The Ohio State University Department of Ophthalmology Columbus, OH April, 1990 University of Minnesota Minneapolis, MN January, 1991 University of Florida Gainesville, FL January, 1991 Jules Stein Eye Institute UCLA Los Angeles, CA March, 1991 University of Arizona Tucson, AZ December, 1991 University of Sao Paulo Sao Paulo, Brazil March, 1992 Johns Hopkins University, The Wilmer Ophthalmological Institute

George A. Williams, M.D. Page 6 The Joseph Koplowitz Memorial Lecture September, 1992 Manhattan Eye, Ear and Throat Hospital New York, NY November, 1994 University of Toronto Toronto, Canada December, 1995 University of Florida Gainesville, FL January, 1996 Cairo University Cairo, Egypt September, 1996 Kresge Eye Institute Wayne State University Detroit, MI April, 1997 Moorfields Eye Hospital London, England July, 1997 Penn State University Hershey, PA February, 1998 Cleveland Clinic Cleveland, OH August, 1998 Kyoto Prefectural University of Medicine

Kyoto, Japan

Keio University School of Medicine Tokyo, Japan March, 1999 McGill University Montreal, Canada Wayne State University Kresge Eye Institute Detroit, MI November, 1999 Ain Shams University Cairo, Egypt November, 2000 Michigan State University East Lansing, MI February, 2001 Medical College of Wisconsin Milwaukee, WI November, 2003 Moorfields Eye Hospital London England St. Paul’s Eye Unit University of Liverpool Liverpool, England

George A. Williams, M.D. Page 7 November, 2005 Wills Eye Hospital Philadelphia, PA February, 2007 Pacific Medical Center San Francisco, CA

North Shore University Hospital New York University School of Medicine Great Neck, NY March, 2008 Emory University Atlanta, GA November, 2008 University of Melbourne Melbourne, Australia March, 2009 Moorfields Eye Hospital Dubai April, 2009 University of Louisville Louisville, KY February, 2010 Kresge Eye Institute Wayne State University Detroit, MI March, 2010 Duke Eye Center Duke University Durham, NC University of North Carolina Chapel Hill, NC Bowman Gray School of Medicine Wake Forest University Winston-Salem, NC April, 2013 Scheie Eye, Perelman School of Medicine University of Pennsylvania Philadelphia, PA May, 2013 Kellogg Eye Center Ann Arbor, MI September, 2013 University of Wisconsin Madison, WI June, 2014 Rush University Chicago, IL April, 2015 Vanderbilt Eye Institute Nashville, TN

George A. Williams, M.D. Page 8 NAMED LECTURESHIPS: March, 1992 The Joseph Koplowitz Memorial Lecture, Johns Hopkins University Baltimore, MD February, 1993 The Randy Campo Memorial Lecture, Phoenix, AZ May, 1994 The Illinois Society for the Prevention of Blindness Lecture The Chicago Ophthalmological Society Chicago, IL June, 1994 The Amini Memorial Lecture The Medical College of Wisconsin Milwaukee, WI June, 2001 Robert Miller Memorial Lecture Northwestern University Medical School Chicago, IL November, 2001 Alex Krill Memorial Lecture The Chicago Ophthalmological Society Chicago, IL November, 2003 Alcon Visiting Lecturer British and Eyrie Vitreoretinal Society Telford, England September 2006 New England Ophthalmology Society Lecture The economic impact of ophthalmic part B drugs in ophthalmology New treatments for neovascular age-related macular degeneration Boston, MA October, 2006 A. Raymond Pilkerton, Jr., M.D. Lecturer Off Label Drug Use The Future of Physician Reimbursement

Georgetown University Hospital Washington National Eye Center February, 2008 Sanford Gifford, M.D. Memorial Lecture

Chicago Ophthalmology Society Illinois Academy of Ophthalmology Chicago, IL

March, 2008 Paul Sternberg, Jr., M.D. Lecture Emory Eye Center Emory University Atlanta, GA

December, 2010 Gerard DeVoe Memorial Lecture Columbia University New York, NY

George A. Williams, M.D. Page 9 June, 2013 Irvine Lecture

USC Doheny Eye Institute Los Angeles, CA

August, 2013 Gertrude D. Pyron Lecture American Society of Retina Specialists (ASRS) Annual Meeting Toronto, Canada June, 2014 Philip C. Hessburg Lectureship Henry Ford Health System

The Gem Theatre Detroit, Michigan

Wayne Won Wong, MD Lectureship Rush University Medical Center Chicago, IL September, 2014 Yasuo Tano, MD Memorial Lecture XXIX Meeting, Club Jules Gonin Zurich Switzerland March, 2015 Taylor Smith, MD Lecture 33rd Annual Aspen Retinal Detachment Society Meeting Snowmass Village, CO April, 2015 William and Grace Snyder Lecture Vanderbilt University Nashville, TN July, 2016 Thomas M. Aaberg Lecture Hilton Head Island, GA December, 2016 Proctor Lecture UCSF San Francisco, CA Alex Krill Memorial Lecture The Chicago Ophthalmological Society Chicago, IL November, 2017 Johns Hopkins University The Wilmer Eye Institute

The David Worthen, MD Lecture Baltimore, MD New England Ophthalmological Society (NEOS) B. Thomas Hutchinson, MD Lecture Tufts University School of Medicine Boston, MA

February, 2018 Medical College of Wisconsin Gary Abrams, MD Lecture Milwaukee, WI September/October, 2018 Dean McGee Eye Institute

Walter Stark Lecture Oklahoma City, OK


EDITORIAL ACTIVITIES:

Editorial Boards: Retina, The Journal of Retinal and Vitreal Diseases, Associate Editor Section Editor, Surgical Techniques

Retina Cases and Brief Reports Current Opinion in Ophthalmology ` Retinal Physician Ocular Surgery News Retina Today, Section Editor

Manuscript Reviewer: Ophthalmology Archives of Ophthalmology American Journal of Ophthalmology Investigative Ophthalmology and Visual Science Retina, The Journal of Retinal and Vitreal Diseases Drug Development Research Current Eye Research American Academy of Ophthalmology Committee on Video Education Journal of Cataract and Refractive Surgery Klumer Academic Publishers Journal of Refractive Surgery Graefe’s Archive for Clinical and Experimental Ophthalmology 1996 - Present Scientific Reviewer, ROPARD Foundation 1990 -1992 Fight for Sight Grant Review Committee 1986 - 1988 Peer Review Committee American Diabetes Association Wisconsin Affiliate 1986 - 1988 Board of Directors American Diabetes Association Wisconsin Affiliate 1986 - 1988 Professional Affairs Committee American Diabetes Association Wisconsin Affiliate PROFESSIONAL ACTIVITIES: 2009 Delegate, American Academy representative to RUC, AMA 2006 - 2009 Alternate American Academy of Ophthalmology representative to RUC, AMA 2005 Associate Board Examiner, American Board of Ophthalmology 2001 Associate Board Examiner, American Board of Ophthalmology 2000-2001 Program Director, Retina 2000, Management of Posterior Segment Disease, American Academy of Ophthalmology 2000 - Present MSMS Committee on Scope of Practice, Michigan State Medical Society

George A. Williams, M.D. Page 11 1999 - Present Associate Examiner of the Board, American Board of Ophthalmology 1999-2000 Past President, The Vitreous Society 1999-2000 Past President, Michigan Ophthalmological Society 1998-1999 Program Committee, Vitreoretinal Update, American Academy of Ophthalmology 1997-1998 President, The Vitreous Society 1995-1997 President, Michigan Ophthalmological Society 1994-1995 President Elect, Michigan Ophthalmological Society 1996 - Present Board Member, ROPARD, Association for Retinopathy of Prematurity and Related

Diseases 1994-1996 Vice President, The Vitreous Society 1994-1996 Program Chairman, The Vitreous Society 1991-1993 Secretary, The Vitreous Society 1988-1990 Representative-at-large, The Vitreous Society 1988-1992 Program Chairman, Michigan Ophthalmological Society 1988-1995 Program Chairman, Dept. of Ophthalmology, William Beaumont Hospital 1992-1994 Secretary, Michigan Ophthalmological Society 1993-1994 Credentials Chairman, The Vitreous Society RESEARCH STUDIES: 2014 - Present Data Safety Monitoring Committee, SCORE-2 Study of Comparative Treatments for Retinal Vein Occlusion 2. National Eye Institute. NCT01969708 2008 – Present Co-Investigator Comparison of Age-related Macular Degeneration Treatment Trials, National Institute of Health, National Eye Institute. NCT00593450 2008 – 2011 Principal Investigator Safety and efficacy of brimonidine intravitreal implant in patients with geographic atrophy due to age-related macular degeneration, Allergan. NCT00658619 2007 – 2012 Principal Investigator A study of encapsulated cell technology implant for patients with atrophic age- related macular degeneration. Neurotech Pharmaceuticals. NCT 00447954 2007 – 2010 Co-Investigator A study of Strontium 90 Beta Radiation with Lucentis to treat age-related macular degeneration. NCT00454389 Principal Investigator A phase I safety study of JSM6427 to Treat AMD. NCT00536016 2006 – 2009 Principal Investigator Anecortave acetate risk reduction trial. NCT00333216 2005-2008 Principal Investigator

A 24-Month Randomized, Double-Masked, Sham Controlled, Multicenter, Phase IIIB Study Comparing Photodynamic Therapy with Verteporfin (Visudyne®) Plus Two Different Dose Regimens Of Intravitreal Triamcinolone Acetonide (1 Mg and 4 Mg) Versus Visudyne® Plus Intravitreal Pegaptanib (Macugen®) In Patients With Subfoveal Choroidal Neovascularization Secondary To Age-Related Macular Degeneration

2005-2008 Principal Investigator

Clinical Evaluation of The Safety of Next Generation Ophthalmic Irrigation


Solution (NGOIS) Compared To BSS Plus For Use During Surgery for Removal of Epimacular Membrane and Vitrectomy

2006-2008 Co-Investigator

Protocol B7A-MC-MBDV Open-Label Treatment for Patients Completing Study B7A-MC-MBCM


[EOP 1012} A Phase 3B/4, Randomized, Active Controlled, Double-Masked, Single Dummy, Multi-Center Comparative Trial, In Parallel Groups, To Compare The Safety and Efficacy Of Intravitreous Injections Of Macugen Given Every 6 Weeks for 54 Weeks (To Be Extended To 102 Weeks As Indicated) Plus Sham Photodynamic Therapy (PDT, To Macugen Plus PDT with Visudyne, In Subjects With Predominantly Classic Subfoveal Choroidal Neovascularization (CNV) Secondary To Age-Related Macular Degeneration (AMD)

2004-2005 Co-Investigator EOP1011} A Phase II Randomized, Double-Masked, Multicenter Trial, in Parallel Groups, To Determine The Safety, Efficacy And Compared to Sham Injections For 30 Weeks in Patients With Recent Vision Loss Due to Macular Edema Secondary To CRVO


EOP1009 A Phase Ii Prospective, Randomized, Double-Masked, Sham-Controlled, Dose-Ranging, Multi-Center Trial To Assess The Effect of Pegaptanib Sodium (Macugen™) on Foveal Thickening On Patients With Exudative Subfoveal Age-Related Macular Degeneration (AMD).

2002-2005 Principal Investigator Alcon C-01-99, “An Evaluation of Efficacy and Safety of Posterior Juxtascleral Injections Of Anecortave Acetate 15mg (0.5ml of 30mg/Ml Anecortave Acetate Sterile Suspension) Versus Visudyne® In Patient With Subfoveal Exudative Age-Related Macular Degeneration (AMD) Eligible For Initial Treatment With Photodynamic Therapy (PDT) Using Visudyne®”. NCT00299507 2002-2005 Co-Investigator EOP1005—A Phase II Randomized, Controlled, Double-Masked, Dose-Finding, Multi- Center Comparative Trial, In Parallel Groups, To Establish The Safety And Preliminary Efficacy Of Intravitreal Injections Of Eye001 (Anti-VEGF Pegylated Aptamer), Given Every 6 Weeks For 12 To 30 Weeks To Patients With Clinically Significant Diabetic Macular Edema (CSME) Involving The Center Of The Macula. 2003-2006 Co-Investigator

EOP1006—An Open-Label, Multi-Center Trial Of The Safety, Tolerability and Pharmacokinetics of 3mg/Eye Intravitreal Injections of Pegaptanib Sodium (Anti-VEGF Pegylated Aptamer) Given Every 6 Weeks For 54 Weeks, in Patients With Exudative Age-Related Macular Degeneration (AMD).


EOP1004—A Phase Ii/Iii Randomized, Double-Masked, Controlled, Dose-Ranging, Multi-Center Comparative Trial, In Parallel Groups, To Establish The Safety and Efficacy Of Intravitreal Injections of Eye001 (Anti-VEGF Pegylated Aptamer) Given Every 6 Weeks For 54 Weeks, In Patients With Exudative Age-Related Macular Degeneration (AMD)

George A. Williams, M.D. Page 13 2004-2006 Co-Investigator

A Phase 1/2 Randomized, Masked, Placebo-Controlled, Single, and Multiple-Dose, Sequential Dose-Escalation Study of The Safety and Efficacy of AG-013958 In Patients With Sub-Foveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration (A4321001)

2003-2006 Co-Investigator Sibling Study of Age-Related Macular Degeneration 2001-2006 Co-Investigator

A Multicenter, Randomized, Masked, Controlled Study To Evaluate Retisert™, An Intravitreal Fluocinolone Acetonide Implant, In The Treatment of Patients With Diabetic Macular Edema: (CDS- Fl-005)


Protocol Fvf3689g: A Phase IIIB, Single-Masked, Multicenter, Randomized Study To Evaluate The Safety And Tolerability Of Ranibizumab In Naïve And Previously Treated Subjects With Choroidal Neovascularization (CNV) Secondary To Age-Related Macular Degeneration (AMD)


Protocol IMT-002: Visioncare Ophthalmic Technologies IMT(implantable miniature telescope) for Patients with Central Vision Impairment associated with Age related macular degeneration or Stargardt’s Macular Dystrophy

2005-2009 Co-Investigator (#206207-009) A Six-month, Phase 3, Multicenter, Masked, Randomized, Sham-controlled Trial (with

six-month open-label extension) to Assess the Safety and Efficacy of 700 g and 350 g Dexamethazone Posterior Segment Drug Delivery System(DEX PS DDS) Applicator System in the Treatment of Patients with Macular Edema following Central Retinal Vein Occlusion or Branch Retinal Vein Occlusion


C-02-60 An evaluation of efficacy and safety of posterior juxtascleral administrations of anecortave acetate for depot suspension (15 mg or 30 mg) versus sham administration I patients (enrolled in study “a” or study “b” at risk for developing sight-threatening choroidal neovascularization (CNV) due to exudative age-related macular degeneration Alcon Laboratories

2003-present Co-Investigator Early Treatment for Retinopathy of Prematurity Phase II 2005- 2009 Co-Investigator

FVF3426g: An Open-label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of ranibizumab in Subjects with Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD) who have completed the Treatment Phase of a Genentech-Sponsored ranibizumab Study


ACU201 A Phase Randomized, double – masked, controlled dose comparison Study of Cand5 for intravitreal injection for the treatment of subfoveal choroidal Neovascularization associated with wet age-related macular degeneration


George A. Williams, M.D. Page 14 Protocol FVF2587G A Phase III, Multicenter, Randomized, Double-masked, Active

Treatment-controlled Study of the Efficacy and Safety of RHUFAB V2 (ranibizumab) compared with Verteporfin (Visudyne) Photodynamic Therapy in Subjects with Predominately Classic Subfoveal Neovascular Age-related Macular Degeneration


FVF 2598 A Phase III, Multicenter, Randomized, Double -masked, Sham Injection-Controlled Study of the Efficacy and Safety of RHUFAB V2 (ranibizumab) in Subjects with Minimally Classic or Occult Subfoveal Neovascular Age-related Macular Degeneration


Protocol FVF2428 A Phase I/II, Single-masked, Multicenter Study of the Safety, Tolerability, and Efficacy of Multiple-Dose Intravitreal Injections of RHUFAB V2 in combination with Verteporfin(Visudyne) Photodynamic Therapy in subjects with Neovascular Age-related Macular Degeneration


EOP 1006 A randomized double-masked, multi-center trial of safety, tolerability and pharmacokinetics of 1 mg/eye and 3 mg/eye intravitreal injections of Pegaptanib sodium (anti-VEGF pegylated aptamer) given every 6 weeks for 54 weeks in patients with exudative age-related macular degeneration

2002-2003 Principal Investigator Visudyne and Diabetic Macular Edema Novartis 2001-2007 Principal Investigator Anti-VEGF for AMD Eyetech 2001-2005 Principal Investigator

C-01-99 An evaluation of efficacy and safety of anecortave acetate versus VISUDYNE with subfoveal exudative AMD eligible for initial treatment with PDT using VISUDYNE

2001-2004 Principal Investigator Oculex Applicator Trial – for persistent macular edema. NCT 00035906 2001-2003 Principal Investigator

Verteporfin Early Retreatment Study, VER Novartis

2001-2003 Co-Investigator Early Treatment of Retinopathy of Prematurity Study National Eye Institute 2001-2002 Principal Investigator

Dexamethasone posterior segment drug delivery system for persistent macular Edema Oculex

1999-2000 Executive Committee Submacular Surgery Trials Study National Eye Institute

George A. Williams, M.D. Page 15 1998-2005 Co-Investigator PKC-DMES and PKC-DRS Clinical Trials Lilly 1997-2003 Co-Investigator, 1997-2000 Principal Investigator, 2000-present TAP, Photodynamic Therapy Study Ciba/QLT 1997-2003 Co-Investigator, 1997-2000 Principal Investigator, 2000-present

VIP, Verteporfin in Photodynamic Therapy Study Ciba/QLT 1997-2001 Co-Investigator

A Randomized Study of the Matrix Metalloprotease Inhibitor AG 3340 in Patients with Subfoveal Choroidal Neovascularization Associated with Age-related Macular Degeneration

Agouron Pharmaceutical 1995-2003 Principal Investigator Submacular Surgery Trials Study Grant Subcontract 5U10EY11547-03 National Eye Institute 1995-2002 Co-Investigator Choroidal Neovascularization Prevention Trial, Fellow and Bilateral (Laser study)

1990 - Present Co-Investigator Age-related Eye Disease Study AREDS National Eye Institute N01-EY-0-2115

1994-1996 Principal Investigator Interferon Therapy for Macular Degeneration, Roche

1994-1996 Principal Investigator Randomized Trial of Transforming Growth Factor Beta in the Treatment of Macular Holes, Celtrix

1983 - 1993 Co-Investigator The Multicenter Randomized Comparison of Silicone Oil and Gas in the Treatment of Proliferative Vitreoretinopathy

National Eye Institute EYO-771

1984 - 1988 Principal Investigator Early Treatment Diabetic Retinopathy Study National Eye Institute No1 EY-7-2136

1983 - 1986 Principal Investigator Topical Indomethacin in Phakic Diabetic Vitrectomy,

George A. Williams, M.D. Page 16 Merck, Sharpe and Dohme $16,000

1987- 1988 Co-principal Investigator Lensectomy Using a 308 nm Endoexcimer Laser System National Eye Institute 1 RO3-EY07379-01, $14,340

1985 - 1988 Co-Investigator Vision Research Training Grant National Eye Institute T32 WY07016 1985 - 1988 Co-Investigator Wisconsin Incidence Cohort Registry of Type I Diabetes 1 RO1 DK36904-O1A1

1988 - 1995 Co-Investigator Endophthalmitis Vitrectomy Study National Eye Institute I U10 EY08589-01 1992 - 1993 Principal Investigator The effect of plasminogen activator type 2 on ocular neovascularization Wm. Beaumont Hospital $49,982 EDUCATIONAL ACTIVITIES: April 2009 – Present Chair, Department of Ophthalmology Oakland University William Beaumont School of Medicine Rochester, Michigan 2001 – Present Chair, Department of Ophthalmology Beaumont Hospitals, Royal Oak, Michigan 1992-2001 Director, Vitreoretinal Fellowship William Beaumont Hospital Royal Oak, Michigan 1984 - 1988 Director of Medical Student Education Department of Ophthalmology Medical College of Wisconsin Milwaukee, Wisconsin Committee Member Research Committee Medical College of Wisconsin Milwaukee, Wisconsin 1985 - 1988 Medical Student Advisor Medical College of Wisconsin Milwaukee, Wisconsin

George A. Williams, M.D. Page 17 Committee Member Introduction to Clinical Medicine Review Committee Milwaukee, Wisconsin 1985-1988 Medical College of Wisconsin Milwaukee, Wisconsin 1987 -1988 Committee Member

Laser Safety Committee Medical College of Wisconsin Milwaukee, Wisconsin EDUCATIONAL AWARDS: 1991 Honor Award American Academy of Ophthalmology 1999 Senior Achievement Award American Academy of Ophthalmology 2002 Crystal Apple for teaching excellence American Society of Retina Specialists 2008 Margherio Resident Teaching Award Department of Ophthalmology, William Beaumont Hospital 2010 Outstanding Academic Excellence Award

“The Triple Threat” William Beaumont Hospital

2013 Gertrude D. Pyron Award American Society Retina Specialists

FELLOWS TRAINED: 1984-85 H. Richard McDonald, M.D. Jerry Neuwirth, M.D. 1985-86 Robert Devenyi, M.D. Fred Lambrou, M.D. 1986-87 Hilel Lewis, M.D. Dennis Han, M.D. 1987-88 Matthew Thomas, M.D. Jeffery Parker, M.D. 1988 Glen Jaffe, M.D. Daniel Schwartz, M.D. 1988-89 Deborah Iverson, M.D. Thomas Ward, D.O. David Bradford, M.D. 1989-91 Ira Orgel, M.D.

George A. Williams, M.D. Page 18 Albert Maguire, M.D. 1990-92 Thierry Verstraeten, M.D. 1991-93 Gregory Fox, M.D. Louis Glazer, M.D. 1992-94 Tarek Hassan, M.D. 1993-94 Philip Ferrone, M.D. 1993-95 Anil Goyal, M.D. 1994-95 Bawa Dass, M.D. 1994-96 Alan Margherio, M.D. 1995-97 Scott Pendergast, M.D. Robin Ross, M.D. 1996-98 David Chow, M.D. 1997-99 Michael Banach, M.D. Daniel Berinstein, M.D. 1998-00 Jonathan Williams, M.D. 1999-01 Richard Kaiser, M.D. Ramin Sarrafizadeh, M.D., Ph.D 2000-02 Claron Alldredge, M.D. 2001-03 Franco M. Recchia, M.D. Saad Shaikh, M.D. 2002-04 Jonathan L. Prenner, M.D. 2003-05 Kimberly Drenser, M.D., Ph.D. Michael Ibarra, M.D. 2004-06 Mandar Joshi, M.D. 2005-07 Michael Lai, M.D., Ph.D. Polly Quiram, M.D., Ph.D. 2006-08 Newman Sund, M.D., Ph.D. 2007-09 David Goldenberg, M.D. Mark Walsh, M.D., Ph.D. 2008-10 Lawrence Ho, M.D. Tushar Ranchod, M.D 2009-11 Lisa Faia, M.D. 2010-12 Caesar K. Luo, M.D.

George A. Williams, M.D. Page 19 Melissa D. Neuwelt, M.D. 2011-13 Emmanuel Chang, M.D., Ph.D Amir Kashani, M.D., Ph.D 2012-14 Eric Nudleman, M.D., Ph.D Joshua Robinson, M.D. 2013-15 Ashkan Abbey, M.D. Ankoor Shah, M.D. 2014-2016 Benjamin Thomas, M.D. Yoshihiro Yonekawa, M.D. 2015-2017 Aristomenis Thanos, M.D. Bozho Todorich, M.D., Ph.D. 2016-Present Irina De la Huerta, M.D., Ph.D Prethy Rao, M.D. Maxwell Stem M.D. 2017-Present Mikel Mikhail, MD Stavros Moysidis, MD Edward Wood, MD-Present Mikel Mikhail, MD 2018-Present Nathan Farley, MD Elizabeth Marlow Lehrburger, MD JOURNAL PUBLICATIONS: 1. Harris GJ, Williams GA, Clarke GP. Sarcoidosis of the lacrimal sac. Arch Ophthalmol 1981;99:1198-1201. 2. Nalbandian RM, Henry RL, Williams GA, Fleischman JA, O'Donnell FE, Reeser FH. Polymyalgia rheumatica and

giant cell arteritis: rational diagnosis and treatment predicated on disordered prostaglandin metabolism. Medical Hypotheses 1981;7:1169-1182.

3. Reeser FH, Fleischman JA, Williams GA, Goldman AI. Efficacy of argon laser photocoagulation in the treatment

of circinate diabetic retinopathy. Am J Ophthalmol 1981;92:762-767. 4. Nalbandian RM, Henry RL, Fleischman JA, Burek L, Williams GA, O'Donnell FE, Diglio CA, Collier BD, Reeser

FH. Erythrocyte-endothelial cell adherence in sickle cell disease, diabetes mellitus and falciparum malaria: adverse effects reversed with piracetam. Medical Hypotheses 1982;8:155-162.

5. Williams GA, Reeser FH, O'Brien WJ, Fleischman JA. Prostacyclin and thromboxane A2 derivatives in

rhegmatogenous retinal detachment. Arch Ophthalmol 1983;101:463-464. 6. Nalbandian RM, Kubicek MF, O'Brien WJ, Nichols B, Henry RL, Williams GA, Goldman AI, Adams D, Teng CM.

Liquid-chromatographic quantification of piracetam. Clin Chem 1983;29:664-666. 7. Williams GA, Hatchell DL, Collier BD, Knobel J. Clearance of human diabetic erythrocytes from the anterior

chamber. Arch Ophthalmol 1984;102:930-931. 8. Topping TM, Williams GA. Xenon endophotocoagulation under air using sodium hyaluronate. Am J Ophthalmol

1984;97:785-786.

George A. Williams, M.D. Page 20 9. Williams GA, Eisenstein R, Schumacher B, Hsiao K, Grant D. Inhibitor of vascular endothelial cell growth in the

lens. Am J Ophthalmol 1984;97:366-371. 10. Aaberg TM, Williams GA. Rubeosis iridis; iris fluorescein angiography and periocular steroids; discussion.

Ophthalmol 1984;91:325. 11. Pellin MJ, Williams GA, Gruen DM, Young CE, Peters MA. Endoexcimer laser: intraocular ablative

photodecomposition. Am J Ophthalmol 1985;99:483-484. 12. Hagen APV, Williams GA. Argon laser treatment of a bleeding iris vascular tuft. Am J Ophthalmol 1986;101:379. 13. Abrams GW, Williams GA, Neuwirth J, McDonald HR. Clinical results of titanium retinal tacks with pneumatic

insertion. Am J Ophthalmol 1986;102:13-19. 14. Koenig SB, McDonald HR, Williams GA, Abrams GW. Penetrating keratoplasty after placement of a temporary

keratoprosthesis during pars plana vitrectomy. Am J Ophthalmol 1986;102:45-49. 15. Baumann MA, Ritch PS, Hande KR, Williams GA, Topping TM, Anderson T. Treatment of intraocular lymphoma

with high-dose ARA-C. Cancer 1986;57:1273. 16. Abrams GW, Thomas M, Williams GA, Burton TC. Management of postoperative suprachoroidal hemorrhage with

continuous infusion air pump. Arch Ophthalmol 1986;104:1455-1458. 17. Reeser FH, Fleischman J, Williams GA, Goldman AI. Efficacy of argon laser photocoagulation in the treatment of

circinate diabetic retinopathy. Contemporary Ophthalmic Forum 1986;4:105-109. 18. Peters MA, Burke JM, Clowry M, Abrams GW, Williams GA. Development of traction retinal detachments

following intravitreal injection of retinal Muller and pigment epithelial cells. Graefe's Clin Arch Ophthalmol 1986;224:554-563.

19. Han D, Lewis H Williams GA. Management of complete iridocorneal apposition following vitrectomy. Am J

Ophthalmol 1987;103:108-109. 20. Lewis H, Han DP, Williams GA. Management of fibrin pupillary block glaucoma after pars plana vitrectomy with

intravitreal gas injection. Am J Ophthalmol 1987;103:180-182.

21. Abrams GW, Williams GA. En bloc excision of diabetic membranes. Am J Ophthalmol 1987;103:302-308. 22. Williams DF, Williams GA, Caya JG, Werner RP, Harrison TJ. Intraocular Echinococcus multilocularis. Arch

Ophthalmol 1987;105:1106-1109. 23. Lambrou FH, Snyder R, Williams GA. The use of tissue plasminogen activator in experimental hyphema. Arch

Ophthalmol 1987;105:995-997. 24. Snyder R, Lambrou FA, Williams GA. Intraocular fibrinolysis using human recombinant tissue plasminogen

activator. Arch Ophthalmol 1987;105:1277-1280. 25. Han DP, Lewis H, Williams GA, Mieler WF, Abrams GW, Aaberg TM. Laser photocoagulation in the acute retinal

necrosis syndrome. Arch Ophthalmol 1987;105:1051-1054. 26. Williams DF, Williams GA, Abrams GW, Jesmanowicz A, Hyde JS. Evulsion of the retina associated with optic

nerve evulsion. Am J Ophthalmol 1987;104:5-9. 27. Lewis H, Abrams GW, Williams GA, Foos RY. Anterior hyaloidal fibrovascular proliferation after diabetic

vitrectomy. Am J. Ophthalmol 1987;104:607-613.

George A. Williams, M.D. Page 21 28. Lambrou FH, Snyder R, Williams GA. Treatment of experimental intravitreal fibrin with tissue plasminogen

activator. Am J Ophthalmol 1987;104:619-623. 29. Chilbert MA, Peak MJ, Peak JG, Pellin MJ, Gruen DM, Williams GA. Effects of intensity and influence upon DNA

single-strand breaks induced by excimer laser radiation. Photochemistry and Photobiology 1987;47:523. 30. Han DP, Mieler WF, Williams GA, Abrams GW. Management of traumatic retinal incarceration with vitrectomy.

Arch Ophthalmol 1988;106:640-645. 31. Lambrou FH, Chilbert M, Mieler WF, Williams GA, Olsen K. A new technique for subchoroidal implantation of

experimental malignant melanoma. Invest Ophthalmol Vis Sci 1988;29:995-998. 32. Jaffe GJ, Green GL, McKay B, Hartz A, Williams GA. Intravitreal clearance of tissue plasminogen activator.

Arch Ophthalmol 1988;106:969-972. 33. Williams GA, Lambrou FH, Jaffe GJ, Snyder RW, Green G, Devenyi RG, Abrams GA. Treatment of postvitrectomy

fibrin formation with intraocular tissue plasminogen activator. Arch Ophthalmol 1988;106:969-972. 34. Jaffe GJ, Williams GA, Mieler WF, Radius RL. Ab interno sclerostomy with a high power argon endolaser. Am J

Ophthalmol 1988;106:391-396. 35. Blumenkranz MS, Kaplan H, Clarkson J, Culbertson WW, Williams GA, Meissmer R, Kleiner RC. Acute multifocal

hemorrhagic retinitis. Ophthalmol 1988;95:1663-1672. 36. Sternberg P, Han DP, Yeo JH, Barr CC, Lewis H, Williams GA, Mieler WF. Photocoagulation to prevent retinal

detachment in acute retinal necrosis. Ophthalmol 1988;95:1389-1393. 37. Han DP, Abrams GW, Williams GA. Regression of disc neovascularization by photocoagulation in the acute

retinal necrosis syndrome. Retina 1988;8:244-246. 38. Jaffe GJ, Mieler WF, Burke JM, Williams GA. Photoablation of ocular melanoma with a high powered argon

endolaser. Arch Ophthalmol 1989;107:113-118. 39. Han DP, Mieler WF, Williams GA, Abrams GW. Management of traumatic retinal incarceration with vitrectomy.

Arch Ophthalmol Chinese Edition 1989;4:71-75. 40. Williams GA, Lambrou FH, Jaffe GJ, Snyder RW, Green G, Devenyi RG, Abrams GA. Treatment of postvitrectomy

fibrin formation with intraocular tissue plasminogen activator. Arch Ophthalmol Chinese Edition 19894:90-93. 41. Williams GA, Abrams GW, Mieler WF. Illuminated retinal picks for vitreous surgery. Arch Ophthalmol 1989;

107:1086. 42. Lean JS, Stern WH, Irvine AR, Azen SP, Williams GA as a member of the Silicone Study Group. Classification of

proliferative vitreoretinopathy used in the silicone study. Ophthalmology 1989;96:765-771. 43. Williams DF, Williams GA, Hartz A, Mieler WF, Abrams GW, Aaberg TM. Results of vitrectomy for diabetic

traction retinal detachments using the en bloc excision technique. Ophthalmology 1989;96:752-758. 44. Jaffe GJ, Lewis H, Han DP, Williams GA, Abrams GW. Treatment of postvitrectomy fibrin pupillary block with

tissue plasminogen activator. Am J Ophthalmol 1989;108:170-175. 45. Lewis H, Aaberg TM, Abrams GW, McDonald HR, Williams GA, Mieler WF. Subretinal membranes in

proliferative vitreoretinopathy. Ophthalmology 1989;96:1403-1415. 46. Jaffe GJ, Abrams GW, Williams GA, Han DP. Tissue plasminogen activator for post vitrectomy fibrin

formation. Ophthalmology 1990;97:184-189.

George A. Williams, M.D. Page 22 47. Williams DF, Williams GA, Burke JM. Clearance of vitreous hemorrhage after panretinal cryotherapy is related to

macrophage influx. Arch Ophthalmol 1990;108:595-597. 48. Williams DF, Bennett SR, Abrams GW, Han DP, Mieler WF, Jaffe GJ, Williams GA. Low dose intraocular tissue

plasminogen activator for treatment of postvitrectomy fibrin formation. Am J Ophthalmol 1990;109:606. 49. Williams GA. Ocular manifestations of systemic disease: hematologic and oncologic disease. Current Opinion in

Ophthalmol 1990;1:181-186. 50. Heidemann DG, Williams GA, Blumenkranz MS. Tissue plasminogen activator and penetrating keratoplasty.

Ophthal Surg 1990;21:364. 51. Abrams GW, Williams GA, Jaffe GJ. Managing postoperative fibrin with tissue plasminogen activator. Vitreoretinal

Surgery and Technology 1990;Vol 2, No 3:1-5. 52. Williams DF, Mieler WF, Williams GA. Posterior segment manifestations of ocular trauma. Retina Vol 10/Suppl.

1990;1, pS35-S44. 53. Han DP, Lewis MT, Kuhn EM, Abrams GW, Mieler WF, Williams GA, Aaberg TM. Relaxing retinotomies and

retinectomies; surgical results and predictors of visual outcome. Arch Ophth 1990;108:694-697. 54. Iverson DA, Trese MT, Orgel IK, Williams GA. Laser photocoagulation for threshold retinopathy of prematurity.

Arch Ophthal 1991;109:1342-1343. 55. Williams GA. Discussion of dissolution of intraocular fibrinous exudates by streptokinase. Ophthalmology 1991;98,

874. 56. Mieler WF, Williams DF, Sneed SR, Williams GA. Systemic therapeutic agents and retinal toxicity. Semin in

Ophthal 1991;6, 45-64. 57. Orgel IK, Williams GA. Peribulbar anesthesia for scleral buckling surgery. Vitreoretinal Surgery and Technology

1992;4:4-5. 58. Chew E, Williams GA, Burton TC, Ferris R. Aspirin effects on the development of cataracts in patients with diabetes

mellitus. Early Treatment Diabetic Retinopathy Study Report Number 16. Arch Ophthalmol 1992;110:339-342. 59. Blumenkranz MS, Ward T, Murphy S, Mieler W, Williams GA, Long J. Applications and limitations of vitreoretinal

biopsy techniques in intraocular large cell lymphoma. Retina 1992;12:S64-S70. 60. Glazer LS, Williams GA. Management of expulsive choroidal hemorrhage. Semin in Ophthal 1993;8;109-113. 61. Verstraeten TC, Chapman C, Hartzer M, Winkler BS, Trese MT, Williams GA. Pharmacologic induction of

posterior vitreous detachment in the rabbit. Arch Ophthalmol 1993; 111:849-854. 62. Williams GA. Current concepts regarding posterior vitreous detachment. Current Opinion in Ophthalmol 1994;

111:10-13. 63. Williams GA. Discussion of vitrectomy for the prevention of macular holes: results of a randomized multi-center

clinical trial. Ophthalmology 1994;101:1055-1060. 64. Verstraeten, TC, Williams GA, Chang S, Cox MS, Trese MT, Moussa M, Friberg TR. Lens sparing vitrectomy with

perfluorocarbon liquid for the primary treatment of giant retinal tears. Ophthalmology 1995;102:17-20. 65. Williams GA. The Changing Face of Vitreoretinal Surgery. Guest Editor. Vitreoretinal Surgery and Technology,

1995;7:(4) 1-8.

George A. Williams, M.D. Page 23 66. Williams GA. Cataract Extraction in Diabetics: A Retinal Surgeon's Perspective. Audio Digest, Ophthalmology,

1996;Vol. 34, No. 10. 67. Williams GA. Discussion of visual field defects after macular hole surgery. Ophthalmology, 1996;Vol. 103, No. 12. 68. Smiddy WE, Pimentel S, Williams GA. Macular hole surgery without using adjunctive additives. Ophthalmic Surg

Lasers, 1997;28:713-717. 69. Thompson JT, Smiddy WE, Williams GA, Sjaarda RN, Flynn HW, Margherio RR, Abrams GW. Comparison of

recombinant transforming growth factor beta-2 and placebo as an adjunctive agent for macular hole surgery. Ophthalmology 1998;105:700-706.

70. Margherio AL, Margherio RR, Hartzer M, Trese, MTT, Williams GA, Ferrone PJ. Plasmin enzyme-assisted

vitrectomy in traumatic pediatric macular holes. Ophthalmology 1998;105:1617-1620. 71. Ferrone PJ, Trese MT, Williams GA, Cox MS. Good visual acuity in an adult population with marked posterior

segment changes secondary to retinopathy of prematurity. Retina 1998;18:335-338. 72. Hassan TS, Williams GA, Pendergast SD. Vitrectomy for clinically significant diabetic macular edema. Ophthalmic

Practice 1998;16:6, 250-255. 73. Williams GA, as a member of the Committee on Ophthalmic Assessment Retinal Panel. Indocyanine green

angiography. Ophthalmology 1998;105:1564-1569. 74. Das A, McGuire PG, Eriqat C, Ober RR, deJuan E, Williams GA, McLamore A, Biswas J, Johnson DW. Human

diabetic neovascular membranes contain high levels of urokinase and metalloproteinase enzymes. Invest Ophthalmol Vis Sci 1999;40:809-813.

75. Chow DR, Williams GA, Trese MT, Margherio RR, Ruby AJ, Ferrone PJ. Successful closure of traumatic macular

holes. Retina 1999;19:405-409. 76. Pendergast SD, Margherio RR, Williams GA, Cox MS. Vitrectomy for Chronic Pseudophakic Cystoid Macular

Edema. Am J Ophthalmol 1999;128:317-323. 77. Berinstein DM, Garretson BR, Williams GA. Ultrasound biomicroscopy in case of anterior hyaloidal fibrovascular

proliferation. Ophthalmic Surg Lasers 1999;Vol.30, No. 9. 78. Williams GA. Diagnostic and therapeutic challenges. Retina 1999;19:559-561. 79. Chew EY, Benson WE, Remaley NA, Lindley AA, Burton TC, Csaky K, Williams GA, Ferris FL and the Early

Treatment Diabetic Retinopathy Study Group. Results of lens extraction in patients with diabetic retinopathy. Early Treatment Diabetic Retinopathy Study Report #25. Arch Ophthalmol 1999;117:1600-1606.

80. Banach MJ, Williams GA. Purtscher's retinopathy and necrotizing vasculitis with gemcitabine therapy. Arch

Ophthalmol 2000;118:726-727. 81. Margherio RR, Margherio AR, Williams GA, Chow DR, Banach DR. Effect of perifoveal tissue dissection in the

management of acute idiopathic full-thickness macular holes. Arch Ophthalmol 2000;118:495-498. 82. McCabe CM, Flynn HW, McLean WC, Brod RD, McDonald HR, Johnson MW, Williams GA, Mieler WF, for the Macroaneurysm Study Group. Nonsurgical management of macular hemorrhage secondary to retinal artery macroaneurysms. Arch Ophthalmol 2000;118:780-785. 83. Williams GA, as part of the American Academy of Ophthalmology Committee on Ophthalmic Procedures Retina

Panel. Macular Translocation. Ophthalmol 2000;107:1015-1018.

George A. Williams, M.D. Page 24 84. Chow DR, Garretson BR, Kuczynski B, Williams GA, Margherio R, Cox MS, Trese MT, Hassan T, Ferrone P.

External versus internal approach to the removal of metallic intraocular foreign bodies. Retina 2000;20:364-369. 85. Sarrafizadeh R, Williams GA. Submacular hemorrhage during scleral buckling surgery treated with an intravitreal air bubble. Retina 2000;20:415-416. 86. Trese MT, Williams GA, Hartzer MK. A new approach to stage 3 macular holes. Ophthalmology 2000;107:1607-

1611. 87. Pendergast PD, Hassan TS, Williams GA, Cox MS, Margherio RR, Ferrone PJ, Garretson BR, Trese MT. Vitrectomy for diffuse diabetic macular edema associated with a taut premacular posterior hyaloid. Am J Ophthalmol 2000;130:178-186. 88. Berinstein DM, Hassan TS Williams GA, Margherio RR, Ruby AJ, Garretson BR. Surgical repair of full- thickness idiopathic macular holes associated with significant macular drusen. Ophthalmol 2000;107:2233-2239.

89. Horn EP, McDonald HR, Johnson RN, Ai E, Williams GA, Lewis JM, Rubsamen PE, Sternberg P Jr., Bhisitkul RB, Mieler WF. Soccer ball-related retinal injuries: a report of 13 cases. Retina 2000;20:604-609.

90. Sarrafizadeh R, Ruby AJ, Hassan TS, Garretson BR, Williams GA, Trese MT, Margherio RR. A comparison of visual results and complications in eyes with posterior chamber intraocular lens dislocation treated with pars plana vitrectomy with lens repositioning or lens exchange. Ophthalmol 2001,108:82-89.

91. Banach MJ, Hassan TS, Cox MS, Margherio RR, Williams GA, Garretson BR, Trese MTT. Clinical course and surgical treatment of macular epiretinal membranes in young subjects. Ophthalmology 2001;108:23-26.

92. Ross RD, Stec LA, Werner JC, Blumenkranz MS, Glazer L, Williams GA. Presumed acquired ocular toxoplasmosis in deer hunters. Retina 2001;21:226-229.

93. Pollack AL, McDonald HR, Everett A, Green WR, Halpern LS, Jampol LM, Leahy JM, Johnson RN, Spencer

WH, Stern WH, Weinberg DV, Werner JC, Williams GA. Sympathetic Ophthalmia associated with pars plana vitrectomy without antecedent penetrating trauma. Retina 2001;21:146-154.

94. Benson WE, Cruickshanks KC, Fong DS, Williams GA, Bloome MA, Frambach DA, Kreiger AE, Murphy RP.

Surgical management of macular holes: a report by the American Academy of Ophthalmology. Ophthalmology 2001;108:1328-1335.

95. Kaiser RS, Trese MT, Williams GA, Cox MS. Adult retinopathy of prematurity: Outcomes of rhegmatogenous

retinal detachments and retinal tears. Ophthalmology 2001;108:1647-1653. 96. Williams JG, Trese MT, Williams GA, Hartzer MK. Autologous plasmin enzyme in the surgical management of

diabetic retinopathy. Ophthalmology 2001;108:1902-1905. 97. Sarrafizadeh R, Hassan TS, Ruby AJ, Williams GA, Garretson BR, Capone A, Trese MT, Margherio RR. Incidence

of retinal detachment and visual outcome in eyes presenting with posterior vitreous separation and dense fundus obscuring vitreous hemorrhage. Ophthalmology 2001;108:2273-2278.

98. Hassan TS Sarrafizadeh R, Ruby AJ, Garretson BR, Kuczynski B, Williams GA. The effect of duration of macular

detachment on results after the scleral buckle repair of primary, macula-off retinal detachments. Ophthalmology 2002;109:146-152.

99. Hassan TS, Williams GA. Counterpoint: To peel or not to peel: Is that the question? Editorial. Ophthalmology.

2002;109:11-12.

George A. Williams, M.D. Page 25 100. Kaiser RS, Berger JW, Williams GA, Tolentino MJ, Maguire AM, Alexander J, Madjarov B, Margherio RR.

Variability in fluorescein angiography interpretation for photodynamic therapy in age-related macular degeneration. Retina 2003;22:683-690.

101. Shaikh S, Ruby AJ, Williams GA. Photodynamic therapy using verteporfin for choroidal neovascularization in

angioid streaks. Am J Ophthalmol 2003;135:1-6. 102. Vandenbelt S, Shaikh S, Capone A, Williams GA. Multifocal Choroiditis Associated With West Nile Virus Encephalitis. (Brief Report) Retina 2003;23:97-99. 103. Shaikh S, Garretson B, Williams GA. Vitreoretinal Degeneration Complicated by Retinal Detachment in Alport

Syndrome. (Brief Report) Retina 2003;23:119-120. 104. Recchia F, Williams GA. Visual Improvement Following Sequential Photodynamic Therapy and Vitrectomy for

Coexisting Macular Hole and Choroidal Neovascularization. (Brief Report) Retina 2003;23:110-112. 105. Costa RA, Farah ME, Cardillo JA, Calucci D, Williams GA. Immediate indocyanine green angiography and optical

coherence tomography evaluation after photodynamic therapy for subfoveal choroidal neovascularization. Retina 2003;23:159-165.

106. Heidemann DC, Williams GA, Hartzer M, Ohanian A, Citron ME. Treatment of ligneous conjunctivitis with topical

plasmin and topical plasminogen. Cornea 2003;22:760-2. 107. Gago LC, Wegner RK, Capone A, Williams GA. Intraretinal hemorrhages and chronic subdural effusions. Case

Report. Retina 2003;23:724-726. 108. Williams GA, Scott IU, Haller JA, Maguire AM, Marcus D, McDonald R. Single-Field Focus Photography for

Diabetic Retinopathy Screening: A Report by the American Academy of Ophthalmology. Ophthalmology 2004;111:1055-1062.

109. Stec LA, Ross RD, Williams GA, Trese TT, Margherio RR, Cox MS. Vitrectomy for chronic macular holes. Retina

2004;24:341-347. 110. Farah ME, Cardillo JA, Luzardo AC, Calucci D, Williams GA, Costa RA. Indocyanine green mediated

photothrombosis for the management of predominantly classic choroidal neovascularization caused by age related macular degeneration. Br J Ophthalmol 2004;88:1055-1059.

111. Willliams, G. The economic realities of photodynamic therapy for treatment of AMD, Vitreoretinal Surgery and

Technology, 2004;13:1-4, August. 112. Williams GA, Accredited fellowships: getting our priorities straight. Retinal Physician, Second Opinions 2004 (1)

No 2. 113. Drenser KA, Williams GA, Fu AD, Egan C, Hykin PG, Dugel PU, Rao PK. Diagnostic and therapeutic challenges.

Progressive bilateral visual loss over the last seven years. Retina 2005;25:778-83. 114. Williams GA. The promise and perils of combination therapy. A discussion of off-label treatments for age-related

macular degeneration. Retinal Physician (2) 2005;No. 5. 115. Williams GA. Proper usage of off-label drugs. Review of Ophthalmology. May 2006, Pages 100-103. 116. Williams GA. Macular holes: the latest in current management. Retina 2006;26(6): S9-S10,. 117. Williams GA. Reimbursement changes needed for physician-administered drugs. Special Report. Retinal Physician,

July/August, 2006, p 58-59.

George A. Williams, M.D. Page 26 118. Hermel M, Mahgoub M, Youssef T, Azrak MI, Rza H, Alldredge C, Trese M, Williams GA, Hartzer M. Safety

profile of the intravitreal streptokinase-plasmin complex as an adjunct to vitrectomy in the rabbit. Graefe’s Arch Clin Exp Ophthalmol, 2006; 244:996-1002.

119. Williams GA, Relationship between macular hole size and the potential benefit of internal limiting membrane

peeling. [Comment. Editorial] Br J Ophthalmol. 2006;90:1216-1217.

120. Costa R, Williams GA. Twofold illumination photodynamic therapy scheme for subfoveal choroidal neovascularization in pathologic myopia: Results from a randomized pilot study. Retina 2006;26: 757-764.

121. Kuppermann, BD, Blumenkranz, MS, Haller, JA, Williams, GA, Weinberg, DV, Chou C, Whitcup SM for the

Dexamethasone DDS Phase II Study Group. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol. 2007;125:309-317.

122. Lai MM, Williams GA. Anatomical and visual outcomes of idiopathic macular hole surgery with internal limiting

membrane removal using low-concentration indocyanine green. Retina 2007;27:477-482. 123. McDonald HR, Williams GA, Scott IU, Haller JA, Maguire AM, Marcus DM. American Academy of

Ophthalmology, Ophthalmic Technology Assessment Committee Retina Panel. Laser scanning imaging for macular disease: a report by the American Academy of Ophthalmology. Ophthalmology 2007;114: 1221-8.

124. Quiram PA, Hassan TS, Williams GA. Treatment of naïve lesions in neovascular age-related macular degeneration with pegaptanib. Retina 2007;27: 851-6.

125. Wu WC, Drenser KA, Capone A, Williams GA, Trese MT. Plasmin enzyme-assisted vitreoretinal surgery in

congenital x-linked retinoschisis . Surgical techniques based on a new classification system. Retina 2007;27: 1079-1085.

126. Wu WC, Drenser KA, Trese MTT, Williams GA, Capone A. Pediatric traumatic macular hole: results of autologous

plasmin enzyme assisted vitrectomy. Am J of Ophthalmol 2007; 144: 668-672. 127. Garretson BR, Pollack JS, Ruby AJ, Drenser KA, Williams GA, Sarrafizadeh R. Vitrectomy for symptomatic

lamellar macular hole. Ophthalmology 2008;115:884-886. 128. Rizzo S, Genovesi-Ebert F, Di Bartolo E, Vento A, Miniaci S, Williams GA. Injection of intravitreal bevacizumab

(Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefes Arch Clin Exp Ophthalmol 2008;246: 837-842.

129. Williams GA. 25-, 23- or 20-gauge instrumentation for vitreous surgery? Eye (Lond). 2008;22:1263-6. 130. Williams GA. Enzymatic vitreolysis for retinal disorders. Review of Ophthalmology2008;87-91. 131. Sonmez, Capone, Jr., Trese, Williams. Vitreomacular traction syndrome: impact of anatomical configuration on

anatomical and visual outcomes. Retina 2008;28: 1207-1214. 132. Williams GA. The economic burden of diabetic macular edema. Retina Today 2009;4: 63-65. 133. Williams GA, Haller JA, Kuppermann BD, Blumenkranz MS, Weinberg DV, Chou C, Whitcup SM; On Behalf Of

the Dexamethasone DDS PHASE II STUDY GROUP. Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. Am J Ophthalmol. 2009; 147: 1048-1054.

134. Williams GA, Surgical efficiencies in the ASC vs hospital-based OR. Retina Today 2009;4: 55-56.

George A. Williams, M.D. Page 27 135. Kaiser RS, Prenner J, Scott IU, Bruckner AJ, Flynn HW, Williams GA; The Microsurgical Safety Task Force:

Evolving Guidelines for Minimizing the Risk of Endophthalmitis Associated with Microincisional Vitrectomy Surgery. Retina 2010;30: 692-699.

136. Blumenkranz MS, Haller JA, Kupperman BD, Williams GA; Correlation of Visual Acuity and Macular Thickness

Measured by Optical Coherence Tomography in Patients with Persistent Macular Edema. Retina 2010;30:1090-1094.

137. Haller JA, Kuppermann BD, Blumenkranz MS, Williams GA, Weinberg DV, Chou C, Whitcup SM; Dexamethasone DDS Phase II Study Group. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol 2010;128:289-296.

138. Williams GA, Predicting visual success in macular hole surgery. Evidence-Based Ophthalmology 2011, Vol. 12,

No. 1.

139. Ho LY, Garretson BR, Ranchod TM, Balasubramaniam M, Ruby AJ, Capone A Jr, Drenser KA, Williams GA, Hassan TS; Study of Intraocular Pressure after 23-gauge and 25-gauge pars plana vitrectomy randomized to fluid versus air fill. Retina 2011;31:1109-1117.

140. Ho V, Ho LY, Ranchod TM, Drenser KA, Williams GA, Garretson BR; Endogenous methicillin-resistant

Staphylococus aureus Endophthalmitis. Retina 2011;31(3):596-601.

141. Zhang K, Hopkins J, Heier J, Birch D, Halperin L, Albini T, Brown D, Jaffe G, Tao W, Williams GA. Ciliary Neurotrophic Factor Delivered by Encapsulated Cell Intraocular Implants for Treatment of Geographic Atrophy in Age-Related Macular Degeneration. PNAS 2011; 108:6241-5.

142. Williams GA, The advent of intraoperative imaging in vitreoretinal surgery. Retina 2011; 31:1332-6.

143. Fecko AM, Ho LY, Walsh MK, Williams GA. Intravitreal bevacizumab and ranibizumab for choroidal

neovascularization secondary to endogenous Endophthalmitis. Retinal Cases & Brief Reports 2011;5:229-232. 144. Chiang A, Kaiser RS, Avery RL, Dugel PU, Eliott D, Shah SP, Heier J, Duker J, Hu AY, Schwartz SD, Scott IU,

Pollack JS, Faia LJ, Williams GA. Endophthalmitis in microincision vitrectomy: outcomes of gas-filled eyes. Retina 2011;31: 1513-7.

145. Dugel PU, Blumenkranz MS, Haller JA, Williams GA, Solley WA, Kleinman DM, Naor J. A Randomized, Dose-Escalation Study of Subconjunctival and Intravitreal Injections of Sirolimus in Patients with Diabetic Macular Edema. Ophthalmology 2012;119:124-31.

145. Williams, GA, Vitreoretinal Surgery Fellowship Training and the Big Disconnect. Is it just a numbers game? Retina 2013; 33:263-264. 146. Luo C, Ruby A, Neuwelt M, Williams GA. Transvitreal fibrinoid pseudoendophthalmitis after diabetic Vitrectomy. Retina 2013; 33(10):2069-74. PMID: 23609127. 146. Kashani AH, Cheung AY, Robinson J, Williams GA. Longitudinal optical density analysis of subretinal fluid after

surgical repair of Rhegmatogenous retinal detachment. Retina. 2015;35(1):149-56. doi: 10.1097/IAE.0000000000000267. PMID:25077533

147. Luo C, Ruby A, Neuwelt M, Williams GA. Reply to PMID 23609127. Retina. 2014;34(7):e17. doi: 10.1097/IAE.0000000000000211. 148. Nudleman E, Witmer MT, Kiss S, Williams GA, Wolfe JD. Central serous chorioretinopathy in patients receiving exogenous testosterone therapy. Retina 2014;34(10):2138-32. PMID: 24946102

George A. Williams, M.D. Page 28 149. Learned D, Nudleman E, Robinson J, Chang E, Stec L, Faia LJ, Wolfe JD, Williams GA. Multimodal imaging of west Nile virus chorioretinitis. Retina. 2014;34(11):2269-74. PMID: 25337661 150. Avery RL, Bakri SJ, Blumenkranz MS, Brucker AJ, Cunningham ET Jr, D’Amico DJ, Dugel PU, Flynn HW Jr, Freund KB, Haller JA, Jumper JM, Liebmann JM, McCannel CA, Mieler WF, Ta CN, Williams GA. Intravitreal Injection Technique and Monitoring: Updated Guidelines of an Expert Panel. Retina. 2014;34 Suppl 12:S1- S18. doi: 10.1097/IAE.0000000000000399. PMID: 25489719 151. Abbey AM, Hussain RM, Shah AR, Faia LJ, Wolfe JD, Williams GA. Sutureless scleral fixation of intraocular lenses; outcomes of two approaches. The 2014 Yasuo Tano Memorial Lecture. Graefes Arch Clin Exp Ophthalmol. 2015;253(1):1-5 doi: 10.1007/s00417-014-2834-9 Epub 2014. PMID: 25367831 153. Rao P, Shah AR, Michelotti MM, Anderson B, Abbey AM, Jain N, Stec L, Lowe L, Johnson MW, Williams GA. Bilateral acute endophthalmitis associated with munchausen syndrome. Retina Cases Brief Report. 2015 Spring, 9(2):177-80. 154. Cheung AY, Anderson B, Stec L, Khandhar P, Williams GA. Bilateral Vaso-occlusive retinal vasculitis with H1N1 influenza A infection. Retina Cases Brief Report 2015: 138-41. doi: 10.1097/ICB.0000000000000118. PMID: 25423042 155. Nudleman E, Franklin MS, Wolfe JD, Williams GA, Ruby AJ. Resolution of subretinal fluid and outer retinal changes in patients treated with ocriplasmin. Retina. 2015 [Epub ahead of print] 156. Shah AR, Abbey AM, Yonekawa Y, Khandan S, Wolfe JD, Trese MT, Williams GA, Capone A Jr. Widefield fluorescein angiography in patients without peripheral disease: A Study of Normal Peripheral Findings. Retina. 2015. PMID: 26583312 157. Shah AR, Williams GA. Regulatory and Economic Considerations of Retinal Drugs. Dev Ophthalmol. 2016;55:376-80. Doi: 10.1159/000438965. Epub 2015. PMID: 26502065 158. Kashani AH, Zhang Y, Capone A, Drenser KA, Puliafito C, Moshfeghi AA, Williams GA, Trese MTT. Impaired retinal perfusion resulting from vitreoretinal traction: a mechanism of retinal vascular insufficiency. Ophthalmic Surgery, Lasers & Imaging Retina. 2016;47(3):1-11. Doi: 10.3928/23258160-20160229-03. PMID: 26985791 159. Yonekawa Y, Thanos A, Abbey AM, Thomas BJ, Todorich B, Faia LJ, Williams GA, Capone A Jr, Wolfe JD, Hassan TS. Ophthalmic Surg Lasers Imaging Retina. 2016 1;47(4):352-5. Doi: 10.3928/23258160-20160324- 08. PMID: 27065375. 160. Dajee KP, Abbey AM, Williams GA. Management of dislocated intraocular lenses in eyes with insufficient capsular support. Curr Opin Ophthalmol. 2016; 27(3):191-5. Doi: 10.1097/ICU.0000000000000260. Review. PMID: 26913739. 161. Shah AR, Abbey AM, Yonekawa Y, Khandan S, Wolfe JD, Trese MT, Williams GA, Capone A Jr. Widefield fluorescein angiography in patients without peripheral disease: A Study of Normal Peripheral Findings. Retina. 2016;36(6):1087-92. Doi: 10.1097/IAE.0000000000000878. PMID: 26583312. 162. Yonekawa Y, Hypes SM, Abbey AM, Williams GA, Wolfe JD. Exacerbation of macular oedema associated with hyperbaric oxygen therapy. Clin Exp Ophthalmol. 2016;44(7)625-626. Doi: 10.1111/ceo.12708. PMID: 26844686 163. Thanos A, Yonekawa Y, Todorich B, Huang N, Drenser KA, Williams GA, Trese MT, Capone A Jr. Spectral- Domain Optical Coherence Tomography in Older Patients With History of Retinopathy of Prematurity. Ophthalmic Surg Lasers Imaging Retina. 2016 1;47(12):1086-1094. Doi: 10.3928/23258160-20161130-02. PMID: 27977831.

George A. Williams, M.D. Page 29 164. Reddy DN, Yonekawa Y, Thomas BJ, Nudleman ED, Williams GA. Long-term surgical outcomes of retinal detachment in patients with Stickler syndrome. Clin Ophthalmol. 2016 10:1531-4. Doi: 10.2147/OPTH.S111526. eCollection 2016. PMID: 27574392 165. Nudleman E, Wolfe JD, Woodward MA, Yonekawa Y, Williams GA, Hassan TS. Worsening anatomic outcomes following aflibercept for neovascular age-related macular degeneration in eyes previously well controlled with ranibizumab. Clinical Ophthalmology 2016:10 1-5. 166. Stem MS, Todorich B, Yonekawa Y, Capone A Jr, Williams GA, Ruby AJ. Incidence and visual outcomes of culture-proven endophthalmitis following dexamethasone intravitreal implant. JAMA Ophthalmol. 2017 135(4):379-382. Doi: 10.1001/jamaophthalmol.2016.5883. PMID: 28208166 167. Todorich B, Williams GA, Faia LJ. Optical coherence tomography angiography findings in susac syndrome. Ophthalmology Retina 2017-03;1:164. 168. Todorich B, Thanos A, Yonekawa Y, Mane G, Hasbrook M, Thomas BJ, Woodward MA, Williams GA, Capone Jr. A, Wolfe JD, Faia LJ, Hassan T. Simultaneous dexatethasone intravitreal implant and anti-VEGF therapy for neovascular age-related macular degeneration resistant to anti-VEGF monotherapy. Journal of VitreoRetinal Diseases 2017. Vol. 1 65-74. 169. Rao P, Lum F, Wood K, Salman C, Burugapalli B, Hall R, Singh S. Parke DW 2nd, Williams GA. Real-World Vision in Age-Related Macular Degeneration Patients Treated with Single Anti-VEGF Drug Type for 1 Year in the IRIS Registry. Ophthalmology. 2017 PMID: 29146306 [Epub ahead of print] 170. De la Huerta I, Williams GA. Rhegmatogenous Retinal Detachment after Pediatric Cataract Surgery. Ophthalmology 2018;125(1):4-5 doi: 10.1016/j.ohtha.2017.08.032. PMID: 29268866 [PubMed-in process]. 171. Todorich B, Stem MS, Kooragayla K, Thanos A, Faia LJ, Williams GA, Hassan TS, Woodward MA, Wolfe JD. Structural analysis and comprehensive surgical outcomes of the sutureless intrascleral fixation of secondary intraocular lenses in human eyes. Retina. 2017 doi: 10.1097/IAW.0000000000001941. [Epub ahead of print] PMID: 29232333. 172. Korot E, Thanos A, Todorich B, Rao P, Stem MS, Williams GA. Use of the Avegant Glyph Head-Mounted Virtual Retinal Projection Display to Perform Vitreoretinal Surgery. Journal of VitreoRetinal Diseases 2017. Doi: 10.1177/2474126417738613.

BOOK CHAPTERS AND LETTERS: 1. Williams GA, Reeser FH. Circulating Prostacyclin and Thromboxane Levels in Patients with Diabetic

Retinopathy. Letter to Editor, Ophthalmology 1983;90:856. 2. Williams GA, Eisenstein R, Schumacher B. Inhibitor of Endothelial Cell Growth on the Lens. Letter to Editor, Am

J Ophthalmol 1984;98:123-124. 3. Aaberg TM, Williams GA. Pharmacology of Retina and Vitreous Surgery. In Surgical Pharmacology of the Eye.

Sears ML, Tarkhanen A (eds.), Raven Press, New York, 1985. 4. Williams GA, Hyndiuk RA. Prevention and Management of Post-Traumatic Endophthalmitis. In Treatment of

Anterior Segment Trauma. Miller D, Stegmann R (eds.), Medicopea, Montreal, 1986. 5. Williams GA. Endoexcimer laser. Letter to Editor, Am J Ophthalmol 1986;101:131. 6. Lewis H, Abrams GW, Williams GA. Anterior Hyaloidal Fibrovascular Proliferation. Letter to Editor, Am J

Ophthalmol 1988;105:433-434.

George A. Williams, M.D. Page 30 7. Williams GA, Aaberg TM, Dudley S. Perimacular Photocoagulation of Presumed Baylisascaris Procyonis in Early

Diffuse Unilateral Subacute Neuroretinitis. In Laser Photocoagulation of Retinal Disease. Schatz H, Yannuzzi L, Gitter K (eds.), Pacific Medical Press, 1988.

8. Williams GA, Aaberg TM. Techniques of Scleral Buckling. In Retina, Vol. III. Ryan SJ (ed.), CV Mosby and

Company, 1989;111-149. 9. Williams GA. Coagulation Disorders. In The Eye and Systemic Disease. Gold DH, Weingeist TA (eds.), Lippincott,

1990;129-131. 10. Williams GA. Platelet Disorders. In The Eye and Systemic Disease. Gold DH, Weingeist TA (eds.), Lippincott,

1990;145-146. 11. Williams GA, Hyndiuk RA. Bacillus Subtilis. In Current Ocular Therapy. Fraunfelder F, Roy FH (eds.), Lippincott 1990;8-10 12. Green WR, Williams GA, Murphy RP, Schachat AP, Olk RJ. Hematologic Diseases in Retinal and Choroidal

Manifestations of Systemic Diseases, Jampol L, Ed, Williams & Wilkins 1991;41-78. 13. Williams GA. Hematologic Disorders in Clinical Ophthalmology. Tasman W and Jaeger E. (eds.), Lippincott, 1991. 14. Williams GA, Blumenkranz MS. Vitreous Humor in Foundations of Clinical Ophthalmology. Tasman W., Jaeger E

(eds.), Lippincott, 1992. 15. Williams GA. Pathogenesis and Management of Post-vitrectomy Fibrin in Current Concepts in Vitreoretinal

Surgery. Lewis H and Ryan S. (eds.), Mosby, 1993. 16. Williams GA, Aaberg TM. Techniques of Scleral Buckling in Retina. Vol III, Ryan S, Ed, Mosby, 1994. 17. Williams GA, Aaberg TM. Techniques of Scleral Buckling in Clinical Ophthalmology. Tasman W and Jaeger E

(eds.), Lippincott, 1994. 18. Williams GA. The Archives Attends. Meeting Report of the 20th Meeting of the Club Jules Gonin in Conjunction

with the 29th Annual Scientific Session of the Retina Society, Bern, Switzerland, September 1-6, 1996, in Arch Ophthalmol/Vol 115. Robin D. Ross, M.D. (section ed.), pg. 135, 1997.

19. Williams GA. Drugs Affecting the Coagulation and Fibrinolysis Pathways, in Textbook of Ocular Pharmacology.

Zimmerman T, Ed, Lippincott-Raven, 1997. 20. Williams GA. Pharmacologic Manipulation of the Vitreous. In Vitreoretinal Surgery of the Injured Eye. Alvara V,

Liggett P (eds), Lippincott-Raven, 1998. 21. Williams GA. Scleral Buckling Surgery in Ophthalmology, Yanoff M and Duker J (eds), Mosby, 1998. 22. Pendergast S, Williams GA: Complications of Macular Hole Surgery in; Macular Hole: Pathogenesis, Diagnosis,

and Treatment. Madreperla S and McCuen B (eds), Butterworth-Heinemann, 1998. 23. Williams GA, Aaberg TM: Techniques of Scleral Buckling. In Retina, Vol III, Ryan S (ed), Mosby, 1999. 24. Williams GA. Coagulation Disorders. In Color Atlas of The Eye and Systemic Disease. Gold DH, Weingeist TA

(eds.), Lippincott, Chapter 28;2000;116-137. 25. Ruby AJ, Williams GA. Surgical Techniques. Simple Vitrectomy: Mechanical Principles, Equipment, Set-up, Core Vitrectomy, Peripheral vitrectomy and Removal of Posterior Hyaloid. Peyman GA, Meffer SA, Conway MD, Chou F (eds.), London, Martin Dunitz Ltd., 2001.

George A. Williams, M.D. Page 31 26. Sarrafizadeh R, Williams GA. Antiphospholipid antibodies and retinal thrombosis in patients without risk factors:

a prospective case-control study. Letter to Editor. Am J Ophthalmol 2001;130 (No. 4):538-539. 27. Williams GA, Malmberg ME.Verteporfin photodynamic therapy in clinical practice.Photodynamic Therapy of

Ocular Diseases. Ed. Gragoudas, Miller, Zografos. Lippincot Williams and Wilkins. 2003; 221-226. 28. Williams GA, Aaberg TM, Jr: Techniques of Scleral Buckling. In Retina, Vol III, Ryan S (ed), Mosby, 2006. 29. Hassan TS, Williams GA. Handbook of Wet Age-Related Macular Degeneration. 2007. Lippincott, Williams

and Wilkins. Philadelphia.

30. Williams GA. Financial and Regulatory Implications of Anti-angiogenic Drugs in Das A and Friberg TR, Eds, Therapy for Ocular Angiogenesis Therapy: Principles and Practice, Wolters Kluwer/Lippincott Williams & Wilkins. Philadelphia, PA, 2010;351-66.

31. Williams GA. Diabetic Macular Edema in Bandello F, Querques G (eds): Retinal Diseases. ESASO Course Series. Basel, Karger, 2012;Vol 1: 99-104.

32. Williams GA. Diabetic Retinopathy in Bandello F. Querques G (eds): Retinal Diseases. ESASO Course Series. Basel, Karger, 2012, Vol 1:90-98.

33. Williams GA. The Office of the Inspector General and You. Retina Today 2013;1-2. 33. Faia L, Williams GA. Scleral Buckling Surgery in Ophthalmology. Yanoff M. and Doker J. In Press. 34. Williams GA. High-Deductible Health Plans: Implications for the Retina Specialist. Retina Today 2014: July/August.

ABSTRACTS: 1. Nalbandian RM, Collier BD, Pelc L, Williams GA, Reeser FH, Henry RL. Reduction of adhesion of diabetic

erythrocytes in plastic petri dish model by piracetam. Blood 58:32a, 1981. 2. Pelc LR, Williams GA, Reeser FH, Collier DB. The effect of piracetam on vitreous hemorrhage in the rabbit.

Pharmacy Practice 1982;17:A-15. 3. Fleischman J, O'Donnell F, Nalbandian R, Williams G, Reeser F, Kodesch F, Koenig G. Piracetam's effect on sickle

red blood cells and diabetic red blood cells as demonstrated in enucleated human eye trabecular meshwork filterability studies. Invest Ophthalmol Vis Sci 1982;22:No. 3, Suppl. 70.

4. Williams GA, Hatchell DL, Collier BD, Knobel J. Clearance of human diabetic erythrocytes from the rabbit anterior

chamber. Invest Ophthalmol Vis Sci 1983;24: 291. 5. Fleischman J, Williams GA, DelMonte M. Piracetam's effects on sickle and diabetic RBCs and on phagocytosis by

cultured human RPE cells: possible ophthalmic clinical implications. Invest Ophthalmol Vis Sci 1983;24:152. 6. Burke J, Abrams G, Aaberg T, Williams G. Chemotaxis and proliferation stimulating activities in human vitrectomy

specimens. Correlation with PVR severity. Invest Ophthalmol Vis Sci 1985;26:283. 7. Koenig SB, Williams GA, Aaberg TM. Pars plana vitrectomy with the Landers-Foulks type II keratoprosthesis.

Ophthalmology 1986;93:Aug. Suppl.,140. 8. Han DP, Lewis H, Williams GA, Mieler WF, Abrams GW, Aaberg TM. Laser photocoagulation in the acute retinal

necrosis syndrome. Invest Ophthalmol Vis Sci 1987;28:9.

George A. Williams, M.D. Page 32 9. Lewis H, Abrams GW, Williams GA, Foos RY. Retrolenticular fibrovascular proliferation following diabetic

vitrectomy. Invest Ophthalmol Vis Sci 1987;28:115. 10. Mieler WF, Chilbert M, Williams GA, Burke JM, Lambrou FH. Endoexcimer ablative photodecomposition of

choroidal melanoma in a rabbit model. Invest Ophthalmol Vis Sci 1987;28:117. 11. Snyder RW, Williams GA, Lambrou FH. Clearance of intraocular fibrin using recombinant human tissue

plasminogen activator. Invest Ophthalmol Vis Sci 1987;28:210. 12. Chilbert M, Williams GA, Fritz K, Pellin M, Gruen D. Capsulotomies using a 308 nm endoexcimer laser in vivo.

Invest Ophthalmol Vis Sci 1988,29: 5. 13. Jaffe G, Mieler WF, Williams GA. Treatment of ocular melanoma with high power argon endophotocoagulation.

Invest Ophthalmol Vis Sci 1988,29:363. 14. Radius RL, Williams GA, Jaffe G. Ab interno sclerostomy using a high power argon laser. Invest Ophthalmol Vis

Sci 1988;29:236. 15. Lewis H, Aaberg TM, Abrams GW, Han DP, Williams GA. Current causes of failure following diabetic vitrectomy.

Invest Ophthalmol Vis Sci 1988;29:220. 16. Williams DF, Williams GA, Abrams GW, Mieler WF, Aaberg TM, Hurtz A. The en bloc excision technique for

diabetic traction detachment. Ophthalmology 1988;95 (Sept. Suppl.):125. 17. Lewis H, Abrams GW, Mieler WF, Williams GA, McDonald HR, Aaberg TM. Retroretinal membranes in proliferative vitreoretinopathy. Ophthalmology 1988;95 (Sept Suppl.):125. 18. Green WR, Murphy RP, Schachat AP, Williams GA, Olk RJ, Retinal and choroidal manifestations of systemic

disease: hematologic diseases. Ophthalmology 1988;95 (Sept. Suppl.):129. 19. Williams GA. Treatment of postvitrectomy fibrin formation with intraocular tissue plasminogen activator. Arch

Ophthalmol 1988;106:1055-1058. 20. Williams GA, Lambrou FH, Jaffe GJ, Snyder RW, Green G, Devenyi RG, Abrams GA. Treatment of postvitrectomy

fibrin formation with intraocular tissue plasminogen activator. Ophthalmology Digest 1989;4:15-16. 21. Han DP, Jaffe GJ, Schwartz DM, Lewis H, Abrams GW, Williams GA, Mieler WF. Risk factors for postvitrectomy

fibrin formation. Invest Ophthalmol Vis Sci 1989;ARVO Abstracts: 272. 22. Jaffe GJ, Abrams GW, Williams GA, Han DP. Treatment of postvitrectomy intraocular fibrin with recombinant

tissue plasminogen activator. Ophthalmology 1989;96 (Sept. Suppl.):95. 23. Das A, Frank RN, Zhang NL, Williams GA, Puklin JE, Brourman ND, Sotolongo LB. Ultrastructural

immunocytochemistry of preretinal membranes in proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 1990;ARVO Abstracts 31:642.

24. Hartzer M, Cheng M, Trese M, Williams GA, McLaughlin W., Bardenstein D., Katsura H. Oxygen-induced

retinopathy of prematurity - an immunocytochemical study of the vitreoretinal interface in an animal model. Invest Ophthalmol Vis Sci 1990;ARVO Abstracts 31:659.

25. Yedavally S, Hartzer M, Williams GA. Plasminogen activator inhibitor levels and activity in the human aqueous

humor. Invest Ophthalmol Vis Sci 1990;ARVO Abstracts 31:2494. 26. Williams GA, Orgel I, Hartzer M, Yedavally S. Laser and cryopexy increase aqueous humor levels of plasminogen

activator inhibitor type 2 in the rabbit. Invest Ophthalmol Vis Sci 1991;ARVO Abstracts 32:507.

George A. Williams, M.D. Page 33 27. Verstraeten T, Chapman C, Minelli E, Cheng M, Stec L, Winkler B, Hartzer M, Trese M, Williams, GA.

Pharmacologically-induced posterior vitreous detachment in a rabbit model. Invest Ophthalmol Vis Sci 1992;ARVO Abstracts 33:810.

28. Das A, Frank R, Puklin J, Williams, GA. Increases in Type IV collagen and fibronectin in basement membranes of

human retinal and choroidal new vessels. Invest Ophthalmol Vis Sci 1992;ARVO Abstracts 33:814. 29. Williams GA, Chapman C, Cheng M. Effect of plasminogen activator inhibitor Type 2 (PAI-2) on

neovascularization. Invest Ophthalmol Vis Sci 1992;ARVO Abstracts 33:1942. 30. Trese M, Orgel I, Hartzer M, Williams GA, Chapman C. Intraocular plasminogen activator inhibitor-2 levels in

premature infant eyes. Invest Ophthalmol Vis Sci 1992;ARVO Abstracts 35:1971. 31. Glazer LC, Williams GA. Management of expulsive choroidal hemorrhage. Semin Ophthalmol 1993;8:109-113. 32. Pimentel SG, El-Rayes EN, Williams GA. A survey of airbag-related ocular injuries. Ophthalmology

1995;102:9A:169. 33. Dass B, Dailey W, Orselli S, Margherio AR, Goyal AK, El-Rayes E, Pimentel S, Winkler B, Hartzer M, Williams

GA, Trese MT. Effect of intravitreal plasmin in rhegmatogenous retinal detachments in a rabbit model. Invest Ophthalmol Vis Sci 1995;ARVO Abstracts, 36:4237.

34. Smiddy WE, Pimentel S, Williams GA. Macular hole surgery without using adjunctive additives. Invest Ophthalmol

Vis Sci 1996;ARVO Abstracts 37:2155, 5474. 35. Pendergast SD, Hartzer M, Dailey W, Williams GA, Cheng M, Trese MT. Fluid-gas exchange following intravitreal

plasmin injection in a rabbit model. Invest Ophthalmol Vis Sci 1996;ARVO Abstracts 37:913, 5195. 36. Banach M, Hartzer M, Cheng M. Williams GA. Immunogold localization of extracellular matrix and cellular

components of epiretinal membranes from patients undergoing macular hole surgery. Invest Ophthalmol Vis Sci 1998;ARVO Abstracts 39:3880, S836.

37. Trese MT, Hartzer MK, Williams GA. Autologous plasmin membrane peeling and irrigation by vitrectomy for stage

3 macular holes. Invest Ophthalmol Vis Sci 1999;ARVO Abstracts 40:4, S178. 38. Coors LE, Altomare F, Thomas MA, Williams GA, McGuire PG and Das AB. Human subretinal neovascular

membranes contain high levels of protease enzymes. Invest Ophthalmol Vis Sci 1999;ARVO Abstracts 40:4, S231. 39. Berinstein DM, Dailey W, Hartzer M, Abdel-Dayem, H, Williams GA, Trese MT. Activation of intravitreal porcine

matrix metalloproteases by plasmin. Invest Ophthalmol Vis Sci 1999;ARVO Abstracts 40:4, S701. 40. Berinstein DM, Garretson BR, Williams GA. Ultrasound biomicroscopy in a case of anterior hyaloidal

fibrovascular proliferation. Ophthalmic Surg Lasers 2000;31:69-70. 41. Ruby AJ, Hassan TS, Sarrafizadeh R, Williams GA. Pars plana vitrectomy for diffuse diabetic macular edema

unresponsive to laser photocoagulation. ARVO Abstracts, 2001. 42. Williams GA, Sarrafizadeh R, Garretson BR, Ruby AJ, Hassan TS, Capone A, Trese MT, Margherio RR. Factors

associated with visual outcome in eyes with acute or delayed expulsive suprachoroidal hemorrhage. ARVO Abstracts, 2001.

43. Sarrafizadeh R, Hassan TS, Ruby AJ, Williams GA, Garretson BR, Capone A, Trese MT, Margherio RR. Incidence

of retinal detachment and visual outcome in eyes with acute posterior vitreous separation and dense vitreous hemorrhage. ARVO Abstracts, 2001.

George A. Williams, M.D. Page 34 44. Williams, GA. J. Haller, B. Kuppermann, M. Blumenkranz, D. Weinberg, S. Whitcup. Evaluation of the safety and efficacy of an intravitreous dexamethasone drug delivery system in patients with persistent diabetic macular edema. 8th Euretina Congress. Vienna 2008. 44. Williams GA, Tao W. A Phase II study of encapsulated CNTF secreting cell implant (NT-501) in patients with

visual acuity impairment associated with atrophic macular degeneration. ARVO abstracts, 2009. 45. Faia LJ, Ranchod TM, Williams GA, Capone Jr, A, Ruby AJ, Hassan TS, Trese MT, Garretson BR. Long-term

interventional outcomes of retinoschisis complicated by retinal detachment. Scientific Poster 533, AAO Annual Meeting. Chicago, IL 2010.

PUBLICATIONS FROM CLINICAL TRIALS: 1. Williams GA, as a member of the Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation

for diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 1. Arch Ophthalmol 1985;103:1796-1806.

2. Williams GA, as a member of the Silicone Oil Study Group. Editorial: Proliferative vitreoretinopathy. Amer J

Ophthalmol 1985; 99:5, 593-595. 3. Williams GA, as a member of the Early Treatment Diabetic Retinopathy Study Research Group. Treatment

techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Ophthalmology 1987;94:761-764.

4. Williams GA, as a member of the Early Treatment Diabetic Retinopathy Study Research Group. Techniques for

scatter and local photocoagulation treatment of diabetic retinopathy. Early Treatment Diabetic Retinopathy Study Report Number 3. Int Ophthalmol Clin 1987;27:254-264.

5. Williams GA, as a member of the Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation

for diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 4. Int Ophthalmol Clin 1987;27:265-272.

6. Williams GA, as a member of the Early Treatment Diabetic Retinopathy Study Research Group. Case reports to

accompany Early Treatment Diabetic Retinopathy Study reports Number 3 and 4. Int Ophthalmol Clin 1987;17:273-333.

7. Williams GA, as a member of the Silicone Oil Study Group. The validity and reliability of photographic

documentation of proliferative vitreoretinopathy. Ophthalmol 1989;96:3, 352-357. 8. Williams GA, as a member of the Silicone Oil Study Group. Classification and documentation of pre-surgical

proliferative vitreoretinopathy. Ophthalmol 1989;96:6, 765-771. 9. Williams GA, as a member of the Silicone Oil Study Group. Intraocular silicone oil versus gas in the management

of proliferative vitreoretinopathy (PVR): A multicenter clinical study. In Freeman HM, Tolentino FI, eds., Proliferative vitreoretinopathy, Springer-Verlag, 1989.

10. Williams GA, as a member of the Early Treatment Diabetic Retinopathy Study Research Group. Early Treatment

Retinopathy Study design and baseline patient characteristics. Early Treatment Diabetic Retinopathy Study Report Number 7, Ophthal 1991;Vol 98:741-756.

11. Williams GA, as a member of the Early Treatment Diabetic Retinopathy Study Research Group. Effects of aspirin

treatment on diabetic retinopathy. Early Treatment Diabetic Retinopathy Study Report Number 8. Ophthal 1991;Vol 98:757-765.

George A. Williams, M.D. Page 35 12. Williams GA, as a member of the Early Treatment Diabetic Retinopathy Study Research Group. Early

photocoagulation for diabetic retinopathy. Early Treatment Diabetic Retinopathy Study Report Number 9. Ophthal 1991;Vol 98:766-785.

13. Williams GA, as a member of the Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic

retinopathy from stereoscopic color fundus photographs - an extension of the modified Airlie House classification. Early Treatment Diabetic Retinopathy Study Report Number 10. Ophthal 1991;Vol 98:786-806.

14. Williams GA, as a member of the Early Treatment Diabetic Retinopathy Study Research Group. Classification of

diabetic retinopathy from fluorescein angiograms. Early Treatment Diabetic Retinopathy Study Report Number 11. Ophthal 1991.Vol 98:807-822.

15. Williams GA, as a member of the Early Treatment Diabetic Retinopathy Study Research Group. Fundus

photographic risk factors for progression of diabetic retinopathy. Early Treatment Diabetic Retinopathy Study Report Number 12. Ophthal 1991;Vol 98:823-833.

16. Williams GA, as a member of the Early Treatment Diabetic Retinopathy Study Research Group. Fluorescein

angiographic risk factors for progression of diabetic retinopathy. Early Treatment Diabetic Retinopathy Study Report Number 13. Ophthal 1991;Vol 98:834-840.

17. Williams GA, as a member of the Early Treatment Diabetic Retinopathy Study Research Group. Aspirin effects on

the development of cataracts in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study Report Number 16. Arch Ophthalmol 1992;110:339-342.

18. Williams GA, as a member of the Silicone Oil Study Group. Vitrectomy with silicone oil or sulfur hexaflouride gas

in eyes with severe proliferative vitreoretinopathy: Results of a randomized clinical trial. Silicone Study Report Number 1. Arch Ophthalmol 1992;110:770-779.

19. Williams GA, as a member of the Silicone Oil Study Group. Vitrectomy with silicone oil or perfluoropropane gas

in eyes with severe proliferative vitreoretinopathy: Results of a randomized clinical trial. Silicone Study Report Number 2. Arch Ophthalmol 1992;110:780-792.

20. Williams GA, as a member of the Early Treatment Diabetic Retinopathy Study Research Group. Pars plana

vitrectomy in the Early Treatment Diabetic Retinopathy Study. Early Treatment Diabetic Retinopathy Study Report Number 17. Ophthal 1992;Vol 99, 9:1351-1357.

21. Williams GA, as part of the Silicone Oil Study Group. Vitrectomy with silicone oil or perfluoropropane gas in eyes

with severe proliferative vitreoretinopathy: Results in Group 1 versus Group 2. Silicone Study Report Number 3. Retina1993;13:279-284.

22. Williams GA, as part of the Silicone Oil Study Group. Intraocular pressure abnormalities in the Silicone Study.

Silicone Study Report Number 4. Ophthal 1993;Vol 100, 11:1629-1635. 23. Williams GA, as part of the Silicone Oil Study Group. Relaxing retinotomy with silicone oil or long-acting gas in

eyes with severe proliferative vitreoretinopathy. Silicone Study Report Number 5. Am J Ophth 1993;Vol 166, 5:557-564.

24. Williams GA, as a member of the Silicone Oil Study Group. The effects of silicone oil removal in the Silicone

Study. Silicone Study Report Number 6. Arch Ophthalmol 1994;112:778-785. 25. Williams GA, as a member of the Silicone Oil Study Group. Reply to the Editor: The letter from Peyman, Greve

and Millsap. Arch Ophthalmol 1994;112:729. 26. Williams GA, as a member of the Silicone Oil Study Group. The incidence of corneal abnormalities in the Silicone

Study. Silicone Study Report Number 7. Arch Ophthalmol.

George A. Williams, M.D. Page 36 27. Williams GA, as a member of the Early Treatment Diabetic Retinopathy Study Research Group. Focal

photocoagulation treatment of diabetic macular edema. Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline. Early Treatment Diabetic Retinopathy Study Report Number 19. Arch Ophthalmol 1995;113:1144-1155.

28. Williams GA, as a member of the Silicone Oil Study Group. Macular pucker in reoperations for proliferative

vitreoretinopathy. Silicone Study Report Number 8. In review. Ophthalmology 1995;102:1884-1891. 29. Williams GA, as a member of the Silicone Oil Study Group. Anterior proliferative vitreoretinopathy in the Silicone

Study. Silicone Study Report Number 9. 30. Williams GA, as a member of the Silicone Oil Study Group. The prognostic utility of the Silicone Study

classification system. Silicone Study Report Number 10. Ophthalmology 1996;103:1092-1099. 31. Williams GA, as a member of the Silicone Oil Study Group. Vitrectomy with silicone oil or long-acting gas in eyes

with severe proliferative vitreoretinopathy: results of additional and long-term follow-up. Silicone Study Report Number 11.

32. Williams GA, as a member of the Age-Related Eye Disease Study. Interferon Alfa-2a is ineffective for patients with

choroidal neovascularization secondary to age-related macular degeneration. Results of a prospective randomized placebo-controlled clinical trial. Pharmacological Therapy for Macular Degeneration Study Group. Arch Ophthalmol 1997;115:865-872.

33. Williams GA, as a member of the Early Treatment Diabetic Retinopathy Study Research Group. Subretinal fibrosis

in diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 23. Arch Ophthalmol 1997;115:873-877.

34. Williams GA, as a member of the Endophthalmitis Vitrectomy Study Group. Additional procedures after the initial

vitrectomy or tap-biopsy in the Endophthalmitis Vitrectomy Study. Ophthalmology 1998;105:707-716. 35. Williams, GA as a member of the Treatment of Age-Related Macular Degeneration with Photodynamic Therapy

(TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 12 randomized clinical trials- TAP Report 1. Arch Ophthalmol 1999;117:1329-1345.

36. Williams GA, as a member of the Early Treatment Diabetic Retinopathy Study Group. Results of lens extraction in

patients with diabetic retinopathy. Early Treatment Diabetic Retinopathy Study Report #25. Arch Ophthalmol 1999;117:1600-1606.

37. Williams GA, as a member of the Treatment of Age-Related Macular Degeneration with Photodynamic Therapy

(TAP) Study Group. Verteporfin (Visudyne) therapy of subfoveal choroidal neovascularization in age-related macular degeneration. One year results of two randomized clinical trials - TAP Report #1. Arch Ophthalmol 1999;117:1339-1345.

38. Williams GA, as a member of the Age-Related Eye Disease Study (AREDS). Design implications AREDS Report

No. 1. Control Clin Trials 1999;20:573-600. 39. Williams GA, as a member of the Submacular Surgery Trials Pilot Study. Submacular Surgery Trials Randomized

Pilot Trial of laser photocoagulation versus surgery for recurrent choroidal neovascularization secondary to age-related macular degeneration: I. ophthalmic outcomes. Submacular Surgery Trials Pilot Study Report Number 1. Am J Ophthalmol 2000;130:387-407.

40. Williams GA, as a member of the Submacular Surgery Trials Pilot Study. Submacular Surgery Trials Randomized

Pilot Trial of laser photocoagulation versus surgery for recurrent choroidal neovascularization secondary to age-


related macular degeneration: II. ophthalmic outcomes. Submacular Surgery Trials Pilot Study Report Number 2. Am J Ophthalmol 2000;130:408-418.

41. Williams GA, as a member of the Endophthalmitis Vitrectomy Study Group. Retina Detachment in the

Endophthalmitis Vitrectomy Study. Arch Ophthalmol 2000;118:1661-1665. 42. Williams GA, as a member of the Treatment of Age-Related Macular Degeneration with Photodynamic Therapy

(TAP) Study Group. verteporfin (Visudyne) therapy of subfoveal choroidal neovascularization in age-related macular degeneration. One year results of two randomized clinical trials - TAP Report #2. Arch Ophthalmol 2001;119:198-207.

43. Williams GA, as a member of the Verteporfin in Photodynamic Therapy (VIP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. One year results of a randomized clinical trial – VIP Report #1. Ophthalmol 2001;108:841-852. 44. Williams GA, as a member of the Verteporfin in Photodynamic Therapy (VIP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. One year results of a randomized clinical trial – VIP Report #2. Am J Ophthalmol 2001;131:541-560. 45. Williams GA, as a member of the Age-Related Eye Disease Study Research Group. The age-related eye disease

study (AREDS) system for classifying cataracts from photographs: AREDS Report No. 4. Am J Ophthalmol 2001;131:167-175.

46. Williams GA, as a member of the Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study

Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with Verteporfin. Two-year results of 2 randomized clinical trials – TAP Report #2. Arch Ophthalmol 2001;119:198-207.

47. Williams GA, as a member of the Age-Related Eye Disease Study Research Group. A Randomized, Placebo-

Controlled, Clinical Trial of High-Dose Supplementation With Vitamins C and E, Beta Carotene, and Zinc for Age-Related Macular Degeneration and Vision Loss: AREDS Report No. 8. Arch Ophthalmol. 2001;119: 1417—1436.

48. Williams GA as a member of the verteporfin Roundtable 2000 and 2001 Participants. Treatment of Age- Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group Principal Investigators, Verteporfin in Photodynamic Therapy (VIP) Study Group Principal Investigators. Guidelines for using verteporfin (Visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. Retina 2002;22:6-18. 49. Rubin GS, Bressler NM. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Effects of verteporfin therapy on contrast sensitivity: results from the Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Investigation - TAP Report No. 4. Retina 2002;22:536- 544. 50. Williams GA as a member of the Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study

Group. verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials -- TAP Report No. 5. Arch Ophthalmol 2002;120:1307-1314.

51. Williams GA as a member of the Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study

Group. Verteporfin therapy for subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP Report No. 3. Arch Ophthalmol 2002;120:1443-1454.

52. Bressler NM, Williams GA as a member of the VIP Study Group. Prognosis for placebo-treated eyes in VIP Report 2. Author reply Am J Ophthalmol 2002;133:295-296.

George A. Williams, M.D. Page 38 53. Bressler NM, Williams GA as a member of the Verteporfin in Photodynamic (VIP) Study Group. Author reply.

Ophthalmology 2002;109:1043-1044. 54. Bressler NM, Williams GA as a member of Verteporfin in Photodynamic (VIP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization. Verteporfin in Photodynamic Therapy Report 2. Am J Ophthalmol 2002;133:168-169. 55. Bressler NM, Williams GA as a member of Verteporfin in Photodynamic (VIP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration. Author reply. Am J Ophthalmol 2002;133:857-859. 56. Clemons TE, Williams GA as a member of Age-Related Eye Disease (AREDS) Study Group. National Eye Institute Visual Function Questionnaire in the Age-Related Eye Disease Study (AREDS). Arch Ophthalmol 2003; 121:211-217. 57. Bressler NM, Williams GA as a member of TAP Study Group. Treatment of age-related macular degeneration with Photodynamic Therapy Study Group Reports No. 1 and 2. Arch Ophthalmol 2001;119:198-207. Arch Ophthalmol 2003;121:1253-68. 58. Miskala PH, Hawkins BS, Williams GA as a member of the Submacular Surgery Trials Research Group. Responsiveness of the National Eye Institute Visual Function Questionnaire to Changes in Visual Acuity. Arch Ophthalmol 2003;121:531-539. 59. Williams, GA as a member of the Age-Related Eye disease Study Research Group. Potential public health impact of age-related eye disease study results: AREDS Report No. 11. Arch Ophthalmol 2003;121:1621-1624. 60. Williams, GA as a member of the Verteporfin In Photodynamic Study Group. Verteporfin Therapy of Subfoveal Choroidal Neovascularization in Pathologic Myopia. 2-year Results of a Randomized Clinical Trial- VIP Report No.3. Ophthalmology 2003; 110:667-673. 61. Williams GA as a member of The Submacular Surgery Trials Research Group. Responsiveness of the National Eye Institute Visual Function Questionnaire to Changes in Visual Acuity. Findings in Patients with Subfoveal Choroidal Neovascularization – SST Report No.1. Arch Ophthalmol 2003;121:531-539.. 62. Williams GA as a member of AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the age-related eye disease study. Report No. 13. Arch Ophthalmol 2004;122:716-726. 63. Williams, GA as a member of AREDS Research Group. Correlation analysis of the in-clinic and telephone batteries from the AREDS cognitive function ancillary study. AREDS Report No. 15. Arch Ophthalmol. 2004;122:723-724. 64. Williams GA as a member of Submacular Surgery Trials Research Group. Health and vision-related quality of life among patients with choroidal neovascularization secondary to age-related macular degeneration at enrollment in randomized trials of Submacular surgery. (Report No. 4) A J Ophthalmol 2004;138:91-108. 65. Williams, GA as a member of Submacular Surgery Trials Research Group. Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: ophthalmic findings. (Report No. 11). Ophthalmology 2004;111:1967-1980. 66. Williams, GA as a member of Submacular Surgery Trials Research Group. Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: quality of life findings. (Report No. 12) Ophthalmology 2004;111:1981-1992.

George A. Williams, M.D. Page 39 67. Williams, GA as a member of Submacular Surgery Trials Research Group. Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: ophthalmic findings. (Report No. 13) Ophthalmology 2004;111:1993-2006. 68. Williams, GA as a member of Submacular Surgery Trials Research Group. Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: quality of life findings. (Report No. 14) Ophthalmology 2004;111:2007-2014. 69. Williams, GA as a member of the VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegatanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351:2805-2816. 70. Williams, GA as a member of the Age-Related Eye Disease Study Research Group. The age-related eye disease study severity scale for age-related macular degeneration. AREDS Report No. 17. Arch Ophthalmol 2005;123:1484-1498. 71. Williams, GA as a member of the Age-Related Eye Disease Study Research Group. A simplified severity scale for age-related macular degeneration. Arch Ophthalmol 2005;123:1570-1574. 72. Williams GA, as a member of Ashley L. Childs & the Submacular Surgery Trials Research Group. Effect of order of administration of health-related quality of life interview instruments on responses. (SST report no. 3) Qual Life Res 2005;14:493-500. 73. Williams GA as a member of as members of the Submacular Surgery Trials Research Group. Histopathologic and ultrastructural features of surgically excised subfoveal choroidal neovascular lesions: SST report no. 7. Arch Ophthalmol 2005;123:914-921. 74. Williams GA as a member of the Submacular Surgery Trials Research Group. Guidelines for interpreting retinal photographs and coding findings in the Submacular Surgery Trials (SST): SST report no. 8. Retina 2005;25:253- 268. . 75. Williams GA as a member of the Submacular Surgery Trials Research Group. Health- and Vision-related Quality of Life Among Patients With Ocular Histoplasmosis or Idiopathic Choroidal Neovascularization at Enrollment in a Randomized Trial of Submacular Surgery: Submacular Surgery Trials Report No. 5. Arch Ophthalmol 2005;123:78-88. 76. Williams, GA as a member of the Age-Related Eye Disease Study Research Group. Responsiveness of the National Eye Institute Visual Function Questionnaire to Progression to Advanced Age-Related Macular Degeneration, Vision Loss, and Lens Opacity. AREDS Report No. 14. .Arch Ophthalmol. 2005;123:1207-1214.. 77. Williams, GA as a member of the Age-Related Eye Disease Study Research Group. Correlation Analysis of the In-Clinic and Telephone Batteries from the AREDS Cognitive Function Ancillary Study. AREDS Report No. 15. Ophthalmic Epidemiology 2005;12:271-277. 78. Williams GA as a member of the VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group. Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: An exploratory analysis. Retina 2005;25:815-827. 79. Williams GA as a member of the Age-Related Eye Disease Study Research Group. Centrum use and progression of age-related cataract in the Age-related eye disease study. Ophthalmology 2006;113:1264-1270. 80. Williams, GA as a member of the Age-Related Eye Disease Study Research Group. Relationship between slow visual processing and reading speed in people with macular degeneration. Vision Res 2007; 47: 2943-2955. 81. Williams, GA as a member of the Age-Related Eye Disease Study Research Group. Change in Area of Geographic Atrophy in the Age-Related Eye Disease Study. AREDS Report No. 26. Ophthalmic Epidemiology. Arch Ophthalmol. 2009; 127: 1168-1174

George A. Williams, M.D. Page 40 82. Williams, GA as a study member. Risk of advanced Age-Related Macular Degeneration after cataract surgery in the AREDS: AREDS report No. 25. Ophthalmology 2009;116:297-303.

83. Williams, GA as a study member. Intravitreous dexamethasone effects on different patterns of diabetic macular edema. Arch Ophthalmol. 2010; 128:642-3. 84. Williams, GA as a study member. Evaluation of the Age-Related Eye Disease Study clinical lens grading system AREDS report No. 31. Ophthalmology 2010:117(11):2112-9.

85. Williams, GA as a member of the Age-Related Eye Disease Study Research Group. Grating visual acuity results in the early treatment for retinopathy of prematurity study. Arch Ophthalmol, 2011; 129:840-6. 86. Williams, GA as a member of the Age-Related Eye Disease Study Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011; 364:1897-908. 87. Williams, GA as a member of the Age-Related Eye Disease Study Group. Risk factors associated with incident cataracts and cataract surgery in the AREDS: AREDS report number 32. Ophthalmology 2011;118:2113-9. 88. Williams, GA as a member of the Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119:1388-98. 89. Williams, GA as a member of the CATT Research Group. Photographic assessment of baseline fundus morphologic features in the Comparison of Age-Related macular Degeneration Treatments Trials. Ophthalmology 2012;119:1634-41. 90. Williams, GA as a member of the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT Research Group). Optical coherence tomography grading reproducibility during the Comparison of Age-related macular Degeneration Treatments Trials. Ophthalmology 2012;119:2549-57. 91. Williams, GA as a member of AREDS2 Research Group. The Age-Related Eye Disease Study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology 2012;119:2282-9. 92. Williams, GA as a member of the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT Research Group). Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age-Related Macular Degeneration Treatment Trials. Ophthalmology 2013; Epub ahead of print. 93. Williams, GA as a member of the Comparison of Age-Related Macular Degeneration Treatments Trials Research Group. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age- related macular degeneration. Ophthalmology 2013;120:122-9 94. Williams, GA as a member of the Comparison of AMD Treatments Trials Research Group. Pharmacogenetics for genes associated with Age-Related macular Degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology 2013; 120:593-9 Epub. 95. Williams, GA as a member of the Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA 2013;309;2005-15. 96. Williams, GA as a member of the Age-Related Eye Disease Study Research Group. Methods and reproducibility of grading optimized digital color fundus photographs in the Age-Related Eye Disease Study 2 (AREDS2 Report Number 2). Invest Ophthalmol Vis Sci. 2013 Jul 8;54(7):4548-54. PMID:23620429

George A. Williams, M.D. Page 41 97. Williams, GA as a member of the Age-Related Eye Disease Study Research Group. Ten-year incidence rates of age-related cataract in the Age-Related Eye Disease Study (AREDS): AREDS report no. 33. Ophthalmic Epidemio. 2013;20:71-81. 99. Williams, GA as a member of the Age-Related Eye Disease Study Research Group. Long-term effects of vitamins

C and E, β-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology. 2013 Aug;120(8):1604-11.

PRESENTATIONS: June, 1980 Prostaglandin mediated mechanisms of retinal vascular permeability. Resident's Day, Medical College of Wisconsin Milwaukee, WI September, 1980 Erythrocyte deformability in diabetic retinopathy. Grand Rounds, Blodgett Memorial Medical Center Grand Rapids, MI March, 1981 Aspirin dosage in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study Executive Committee Meeting Chicago, IL April, 1981 Sarcoidosis of the lacrimal sac. Theobald Society Milwaukee, WI June, 1981 Prostacyclin and thromboxane A2 derivatives in rhegmatogenous subretinal fluid. Resident's Day, Medical College of Wisconsin Milwaukee, WI October, 1981 The effect of piracetam on vitreous hemorrhage in the rabbit. International Congress on Hematological and Metabolic

Aspects of Piracetam Heidelberg

Reduction of adhesion of diabetic erythrocytes in plastic petri dish model by piracetam. International Congress on hematological and Medical

Aspects of Piracetam Heidelberg

Quantitative analysis of serum and aqueous piracetam concentration by high performance liquid chromatography.

International Congress on Hematological and Medical Aspects of Piracetam Heidelberg

May, 1982 Aspirin dosage in diabetic retinopathy. Third International Symposium on Drug-Induced Side Effects and Ocular Toxicology Milwaukee, WI

George A. Williams, M.D. Page 42 October, 1982 Salicylates and diabetic retinopathy. Symposium on Ocular and Medical Management of Diabetes Milwaukee, WI Piracetam-induced deformability in sickle cell and diabetic erythrocytes. Tenth International Symposium on Nootropic Agents Paris, France February, 1983 Management of acute vitreous hemorrhage. Symposium on Evaluation and Management of Peripheral Retinal Disease Milwaukee, WI June, 1983 Clearance of diabetic erythrocytes Resident's Day, Medical College of Wisconsin Milwaukee, WI February, 1984 Retinal arterial occlusive disease Mechanism of vascular injury. Symposium on Retinal Vascular Disease Milwaukee, WI June, 1984 Angiogenesis inhibitors in the lens Resident's Day, Medical College of Wisconsin Milwaukee, WI February, 1985 Uveal melanocytic tumors Symposium on Ocular Tumors Milwaukee, WI June, 1985 Endoexcimer laser Resident's Day, Medical College of Wisconsin Milwaukee, WI October, 1985 Visiting Professor University of Texas Medical Board Galveston, TX

Toxic retinopathies

American College of Surgeons Chicago, IL Prevention and management of posterior segment complications in cataract surgery American Academy of Ophthalmology San Francisco, CA February, 1986 Ocular larval migrans Uveitis Symposium Milwaukee, WI March, 1986 Role of antithrombin II in retinal vascular disease Macula Society Boca Raton, FL

Antithrombin II in the postoperative fibrin response Vail Vitrectomy Meeting Vail, CO

George A. Williams, M.D. Page 43 Endoexcimer laser for vitreous surgery Vail Vitrectomy Meeting Vail, CO July, 1986 Single strand breaks in DNA from 308 nm excimer exposure Gordon Conference, Lasers in Medicine NH October, 1986 Management of intraocular foreign bodies Symposium on Ocular Trauma Milwaukee, WI November, 1986 Pars plana vitrectomy with the Landers-Foulks Type II keratoprosthesis video program American Academy of Ophthalmology New Orleans, LA Perimacular photocoagulation of presumed Baylisascaris procyonis in early diffuse unilateral

subacute neuroretinitis International Laser Symposium New Orleans, LA

Prevention and management of posterior segment complications in cataract surgery. Course 347

American Academy of Ophthalmology New Orleans, LA February, 1987 Pathophysiology of diabetic retinopathy Symposium on Diabetic Retinopathy Milwaukee, WI March, 1987 Visiting Professor University of Texas Medical Board Department of Ophthalmology Galveston, TX April, 1987 Current concepts in diabetic vitrectomy. Regional Update Course American Academy of Ophthalmology June, 1987 Multifocal Best's macular dystrophy Macula Society Cannes, France September, 1987 Photocoagulation for diabetic macular edema Current Controversies in Ophthalmology Fall Symposium, Medical College of Wisconsin November, 1987 Retinal toxicity of systemic therapeutic agents. Course 721 American Academy of Ophthalmology Dallas, TX

Prevention and management of posterior segment complications of cataract surgery Course 508 American Academy of Ophthalmology

George A. Williams, M.D. Page 44 Dallas, TX Advanced surgery and management for the vitreoretinal surgeon Course 430 American Academy of Ophthalmology Dallas, TX Discussion of heparin prophylaxis for post-vitrectomy intraocular fibrin American Academy of Ophthalmology Dallas, TX December, 1987 En bloc resection of diabetic membranes Vitreous Society St. Thomas, Virgin Islands

Lasers in ophthalmology

American College of Surgeons Milwaukee, WI February, 1988 Ocular inflammation in children Symposium on Retinal Diseases in Children Milwaukee, WI March, 1988 Visiting Professor Kuwait University, School of Medicine Kuwait April, 1988 Prevention of endophthalmitis Regional Update Course American Academy of Ophthalmology Chicago, IL June, 1988 Intraocular tissue plasminogen activator Retina Society Philadelphia, PA July, 1988 Traumatic retinopathies National Eye Trauma Symposium Milwaukee, WI October, 1988 Prevention and management of posterior segment complications of cataract surgery Course 311 American Academy of Ophthalmology Las Vegas, NV

Advanced surgery and management for the vitreoretinal surgeon Course 327 American Academy of Ophthalmology

Las Vegas, NV Retinal toxicity of systemic therapeutic agents

Course 516 American Academy of Ophthalmology Las Vegas, NV

Endophotocoagulation: indications, techniques, and complications

George A. Williams, M.D. Page 45 Course 402 American Academy of Ophthalmology Las Vegas, NV Subretinal membranes in proliferative vitreoretinopathy American Academy of Ophthalmology Las Vegas, NV Detection of diabetic macular edema. Ophthalmoscopy versus photography - Early Treatment Diabetic

Retinopathy Study Report Number 5 As a member of the Early Treatment Diabetic Retinopathy Study Group American Academy of Ophthalmology Annual Meeting Las Vegas, NV November, 1988 Ophthalmic lasers Michigan State Medical Society Detroit, MI December, 1988 Further experience with intraocular tissue plasminogen activator Vitreous Society Scottsdale, AZ February, 1989 Advanced Vitrectomy Course Sarasota, FL March, 1989 Intraocular fibrinolytic therapy Vail Vitrectomy Meeting Vail, CO

June, 1989 Acquired toxoplasmosis in immunocompetent individuals Combined Meeting of the Retina and Macula Societies Boston, MA August, 1989 Treatment of diabetic macular edema High power argon endophotocoagulation Michigan Ophthalmological Society; Mackinac Island, MI September, 1989 Management of diabetic traction detachments Proliferative vitreoretinopathy course Diabetic macular edema Pan American Association of Ophthalmology Rio De Janeiro

Intraocular fibrinolytic therapy Massachusetts Eye and Ear Infirmary Harvard University Boston, MA

October, 1989 Intraocular fibrinolytic therapy Columbus Ophthalmology Society Columbus, OH

Current concepts in the management of diabetic traction detachments

George A. Williams, M.D. Page 46 The Ohio State University Columbus, OH November, 1989 Systemic therapeutic agents and retinal toxicity American Academy of Ophthalmology Course 312 New Orleans, LA

Endophotocoagulation: indications, techniques and complications American Academy of Ophthalmology Course 360 New Orleans, LA Avoidance and management of posterior segment complications of cataract surgery American Academy of Ophthalmology Course 519 New Orleans, LA Pars plana vitrectomy in the management of macular diseases American Academy of Ophthalmology Course 626 New Orleans, LA November, 1989 Advanced surgery and management for the vitreoretinal surgeon American Academy of Ophthalmology Course 731 New Orleans, LA

Ocular manifestations of systemic disease Michigan State Medical Society Dearborn, MI December, 1989 Further experience with tissue plasminogen activator therapy Vitreous Society Orlando, FL January, 1990 Advanced Vitreoretinal Course Sarasota, FL

Retinal manifestations of systemic diseases Metropolitan Ophthalmic Resident Education Program Shanty Creek Bellaire, MI February, 1990 Subretinal hemorrhage and central serous chorioretinopathy Macula Society Maui, HI March, 1990 Retinal breaks and retinal detachment Management of retinal detachment Peripheral retinal changes Ophthalmology Review Course Osler Institute Detroit, MI April, 1990 University of Minnesota Review Course

George A. Williams, M.D. Page 47 Management of hyphema Keratoprosthesis techniques Traumatic retinopathy Minneapolis, MN Ultrastructural immunocytochemistry of preretinal membranes in proliferative diabetic

retinopathy ARVO Sarasota, FL June, 1990 Current Problems in Ophthalmology Annual Department of Ophthalmology Meeting Medical College of Wisconsin Kohler, WI September, 1990 Intraocular fibrinolytic mechanisms Spectrum '90 Troy, MI November, 1990 Endophotocoagulation, indications, techniques and complications American Academy of Ophthalmology Atlanta, GA Avoidance and management of posterior segment complications of cataract surgery American Academy of Ophthalmology Atlanta, GA

Advanced surgery and management for the vitreoretinal surgeon American Academy of Ophthalmology

Atlanta, GA Pars plana vitrectomy in the management of macular disease

American Academy of Ophthalmology Atlanta, GA January, 1991 Intraocular foreign bodies Endophthalmitis Vitrectomy Study Treatment of diabetic macular edema University of Florida Gainesville, FL

Intraocular fibrinolytic mechanisms Vitreous Society Hawaii

Intraocular fibrinolysis Jules Stein Eye Institute UCLA Los Angeles, CA February, 1991 Effect of laser on intraocular plasminogen activator release Macula Society Orlando, FL March, 1991 Trauma retinopathy Mechanisms of retinal neovascularization

George A. Williams, M.D. Page 48 University of Arizona Tucson, AZ June, 1991 Ocular fibrinolytic mechanisms Current Concepts in Ophthalmology Annual Eye Institute Meeting The American Club Kohler, WI July, 1991 Evaluation and management of intraocular foreign body UIC Eye Center The University of Illinois Chicago, IL September, 1991 Biochemical effects of laser photocoagulation Vitreous Society Paris, France

Current concepts in cystoid macular edema University of Arkansas Arkansas Ophthalmological Society October, 1991 Advanced surgery and management for the vitreoretinal surgeon American Academy of Ophthalmology Course 330

Anaheim, CA Pars plana vitrectomy in the management of macular diseases

American Academy of Ophthalmology Course 348

Anaheim, CA Systemic therapeutic agents and retinal toxicity American Academy of Ophthalmology - Course 659

Anaheim, CA December, 1991 Vitreoretinal surgery Sao Caetano dos—l Hospital Sao Paulo, BRAZIL February, 1992 Traumatic Retinopathy Medical and surgical treatment of cystoid macular edema Early Treatment of Diabetic Retinopathy Study Results Montana Academy of Ophthalmology Big Sky, MT March, 1992 Intraocular plasmin-mediated proteolysis Spots and Dots Johns Hopkins/Wilmer Baltimore, MD April, 1992 Subretinal fibrinolytic therapy Wills Eye Hospital Philadelphia, PA Duke Advanced Vitreoretinal Surgery Course


Duke University Eye Center Durham, NC September, 1992 Effect of plasminogen activator inhibitor type 2 (PAI-2) on neovascularization 25th Annual Retina Society Meeting New York City, NY October, 1992 Management of post-operative endophthalmitis A Clinical Day in Ophthalmology Continuing Education in Ophthalmology Retina Topics for the General Ophthalmologist New Hyde Park, NY

Management of cystoid macular edema A Clinical Day in Ophthalmology Continuing Education in Ophthalmology Retina Topics for the General Ophthalmologist New Hyde Park, NY

Plasmin mediated proteolysis for induction of posterior vitreous detachment 10th Annual Meeting of the Vitreous Society La Guna Niguel, CA Spots and Dots Greater New York Vitreoretinal Lecture Series Manhattan Eye, Ear and Throat Hospital New York, NY November, 1992 Advanced surgery & management for the vitreoretinal surgeon American Academy of Ophthalmology Meeting Dallas, TX

Systemic therapeutic agents & retinal toxicity American Academy of Ophthalmology Meeting Dallas, TX November, 1992 Pars plana vitrectomy in the management of macular diseases American Academy of Ophthalmology Meeting Dallas, TX February, 1993 Current concepts of diabetic macular edema 19th Annual Frontiers in Ophthalmology Shaw Eye Center Scottsdale, AZ Medical and surgical management of cystoid macular edema 19th Annual Frontiers in Ophthalmology Shaw Eye Center Scottsdale, AZ April, 1993 Proteolytic mechanisms in ocular neovascularization Advanced Vitreoretinal Symposium The Eye Institute, Medical College of Wisconsin Kohler, WI

April, 1993 Management of posterior segment complications during cataract surgery

George A. Williams, M.D. Page 50 77th Annual Clinical Assembly of the Osteopathic College of Ophthalmology

American Osteopathic Colleges of Ophthalmology and Otolaryngology, Head and Neck Surgery Tucson, AZ May, 1993 Ocular manifestations of systemic diseases St. Mary Hospital CME Lecture St. Mary Hospital Livonia, MI November, 1993 Pars plana vitrectomy in the management of macular diseases American Academy of Ophthalmology Chicago, IL

Advanced surgery and management of the vitreoretinal surgeon American Academy of Ophthalmology Chicago, IL Discussion of the Macular Hole Study American Academy of Ophthalmology Chicago, IL Subretinal thrombolytic therapy New Dimensions in Retina Chicago, IL December, 1993 Subretinal thrombolytic therapy for macular hemorrhage Vitreous Society St. Thomas, U.S.V.I. January, 1994 Pathogenesis and natural history of diabetic retinopathy Inflammatory retinitis Retinal spots and dots Midwinter Laser Course and Fluorescein Angiography Workshop Washington University St. Louis, MO Inflammatory retinitis Midwinter Laser Course and Fluorescein Angiography Workshop Washington University, St. Louis

Retinal spots and dots Midwinter Laser Course and Fluorescein Angiography Workshop Washington University St. Louis, MO May, 1994 Molecular biology and vitreoretinal surgery: cold steel and hot molecules Current concepts in macular hole surgery Subretinal surgery for macular degeneration Illinois Society for the Prevention of Blindness Chicago Ophthalmological Society Chicago, IL

Current concepts in macular hole surgery Illinois Society for the Prevention of Blindness Chicago Ophthalmological Society Chicago, IL

George A. Williams, M.D. Page 51 Subretinal surgery for macular degeneration Illinois Society for the Prevention of Blindness Chicago Ophthalmological Society Chicago, IL June, 1994 Amini Memorial Lecture The Medical College of Wisconsin Milwaukee, WI

The medical & surgical treatment of macular disorders

Vitrectomy for choroidal neovascularization Vitrectomy and the use of tPA for subretinal hemorrhage The Retina Institute of Maryland Annapolis, MD

Vitrectomy for choroidal neovascularization The Retina Institute of Maryland

Annapolis, MD Vitrectomy and the use of tPA for subretinal hemorrhage The Retina Institute of Maryland Annapolis, MD October, 1994 Techno-legal and socioeconomic issues Vitreoretinal Interfaces San Francisco, CA

Pars plana vitrectomy in the management of macular diseases American Academy of Ophthalmology San Francisco, CA

Systemic therapeutic agents and retinal toxicity American Academy of Ophthalmology San Francisco, CA Posterior segment complications of anterior segment surgery: cystoid macular edema American Academy of Ophthalmology San Francisco, CA November, 1994 Molecular biology and vitreoretinal surgery Visiting Professor University of Toronto Toronto, Canada Retinal inflammatory syndromes Visiting Professor University of Toronto Toronto, Canada

Vitreous disorders Visiting Professor University of Toronto Toronto, Canada February, 1995 Molecular biology in vitreoretinal surgery Alumni Post Graduate Course

George A. Williams, M.D. Page 52 Emory University Atlanta, GA Retinal inflammatory syndromes Alumni Post Graduate Course Emory University Atlanta, GA May, 1995 Effect of intravitreal plasmin in rhegmatogenous retinal detachment in a rabbit model Association for Research in Vision and Ophthalmology (ARVO) Ft. Lauderdale, FL August, 1995 Adjunctive therapies for macular hole: plasmin and chondroitinase The Vitreous Society 13th Annual Meeting London, England October, 1995 The Cutting Edge: Diabetic Retinopathy Atlanta, GA A new complication of macular hole surgery American Academy of Ophthalmology Atlanta, GA

Retinal toxicity of systemic therapeutic agents American Academy of Ophthalmology Atlanta, Georgia

December, 1995 Current concepts in macular holes Visiting Professor University of Florida Gainesville, FL

Retinal inflammatory syndromes

Visiting Professor University of Florida Gainesville, FL January, 1996 Visiting Professor Al-Galaa Family Military Hospital Cairo, Egypt February, 1996 Therapeutic implications of the Endophthalmitis Vitrectomy Study Guest Faculty and Panel Member Squaw Valley Retinal Symposium Squaw Creek, CA

Enzyme-mediated vitrectomy techniques Guest Faculty and Panel Member Squaw Valley Retinal Symposium Squaw Creek, CA Subretinal thrombolytic therapy Guest Faculty and Panel Member Squaw Valley Retinal Symposium Squaw Creek, CA

George A. Williams, M.D. Page 53 Cataract extraction in diabetics: a retinal surgeon's perspective Guest Speaker Research Study Club Murrieta, CA Management of dislocated IOL and crystalline lens fragments Guest Speaker Research Study Club Murrieta, CA

Current concepts in cystoid macular edema Guest Speaker Research Study Club Murrieta, CA

Current management of endophthalmitis: what the Early Vitrectomy Study means Guest Speaker Research Study Club Murrieta, CA

Spots and dots: differential diagnosis of retinal inflammatory disorders Guest Speaker Research Study Club Murrieta, CA March, 1996 A survey of airbag-related ocular injuries Vail Vitrectomy Meeting Vail, CO April, 1996 Biochemical markers of micropulsed diode photocoagulation Suncoast Retina Research Forum Sarasota, FL

May, 1996 Lasers -- what is useful and new West Michigan Retina Symposium Associated Retinal Consultants, P.C. Grand Rapids, MI

Macular holes West Michigan Retina Symposium Associated Retinal Consultants, P.C. Grand Rapids, MI July, 1996 Review of clinical research and Infinitech clinical trial results The New Age of Perfluorocarbon Liquids Infinitech, Inc. Chicago, IL Review of clinical research and Infinitech clinical trial results The New Age of Perfluorocarbon Liquids Infinitech, Inc. Chicago, IL

Review of clinical research and Infinitech clinical trial results The New Age of Perfluorocarbon Liquids Infinitech, Inc. Chicago, IL

George A. Williams, M.D. Page 54 Complications of perfluorocarbon liquids The New Age of Perfluorocarbon Liquids Infinitech, Inc. Chicago, IL September, 1996 Biochemical markers of micropulsed diode photocoagulation XXth Meeting of the Club Jules Gonin & 29th Annual Scientific Session of the Retina Society Berne, Switzerland October, 1996 Management of complex retinal detachment Vitreoretinal Frontiers 1996 Annual Meeting of the American Academy of

Ophthalmology - Centennial Meeting Chicago, IL

Systemic therapeutic agents and retinal toxicity Instruction Course #145 1996 Annual Meeting of the American Academy of

Ophthalmology - Centennial Meeting Chicago, IL November, 1996 Management of the red eye in the primary care practice 1996 Michigan State Medical Society Annual Scientific Meeting Lansing, MI January, 1997 Macular hole surgery: going bare Retina '97 - An Advanced Vitreoretinal Course for the Retina Specialist Maui, HI

Visual field defects following vitrectomy Retina '97 - An Advanced Vitreoretinal Course for the Retina Specialist Maui, HI

Subretinal surgery: The SST Retina '97 - An Advanced Vitreoretinal Course for the

Retina Specialist Maui, HI The Endophthalmitis/Vitrectomy Study (EVS) Retina '97 - An Advanced Vitreoretinal Course for the Retina Specialist Maui, HI Enzymatic vitreous surgery Retina '97 - An Advanced Vitreoretinal Course for the Retina Specialist Maui, HI

Current concepts in the management of dislocated intraocular lenses and crystalline lens fragments Milwaukee Ophthalmological Society 1997 Annual Meeting Milwaukee, WI

George A. Williams, M.D. Page 55 Cataract extraction in diabetes Milwaukee Ophthalmological Society 1997 Annual Meeting Milwaukee, WI April, 1997 Role of intraoperative adjunctive substances The Royal College of Ophthalmologists Annual Congress Birmingham, England May, 1997 New chemical agents in the treatment of proliferative vitreoretinopathy

IV International Congress of the Pan Arab Council of Ophthalmology & The Jordanian Ophthalmological Society in Collaboration with the Afro-Arab Ophthalmological Society

Amman, Jordan

The management of retained lens particles after phacoemulsification IV International Congress of the Pan Arab Council of Ophthalmology & The Jordanian Ophthalmological Society in Collaboration with the Afro-Arab Ophthalmological Society

Amman, Jordan Controversies in vitreoretinal surgery

IV International Congress of the Pan Arab Council of Ophthalmology & The Jordanian Ophthalmological Society in Collaboration with the Afro-Arab Ophthalmological Society

Amman, Jordan July, 1997 Penn State Therapeutic options in subfoveal neovascularization Hershey, PA September, 1997 Enzymatic vitrectomy Vitreoretinal Disease Update Wills Eye Hospital Philadelphia, PA

Vitrectomy for diabetic macular edema Vitreoretinal Disease Update Wills Eye Hospital Philadelphia, PA October, 1997 Vitrectomy for diabetic macular edema associated with a taut posterior hyaloid Vitreoretinal Update 1997 American Academy of Ophthalmology Subspecialty Day San Francisco, CA January, 1998 Ultrastructural immunohistochemical analysis of the vitreoretinal juncture: Implications for

enzymatic vitrectomy St. Christoph Vitrectomy Meeting St. Christoph am Arlberg (AUSTRIA) February, 1998 Management of dislocated lens fragments Cleveland Clinic Cleveland, OH

Cataract extraction and macular degeneration Cleveland Clinic Cleveland, OH Cystoid macular edema

George A. Williams, M.D. Page 56 Cleveland Clinic Cleveland, OH March, 1998 Cataract extraction in diabetes Oregon Academy of Ophthalmology Portland, OR Retinal inflammatory syndromes: spots and dots Oregon Academy of Ophthalmology Portland, OR

Current concepts in management of dislocated crystalline lens fragments Oregon Academy of Ophthalmology Portland, OR Therapeutic options in subfoveal neovascularization Oregon Academy of Ophthalmology Portland, OR June, 1998 Enzyme-assisted vitrectomy for traumatic macular holes Ophthalmic Challenges in the New Millennium Update for Anterior and Posterior Segment Surgeons

Rush-Presbyterian-St. Luke's Medical Center Department of Ophthalmology, Rush Medical College Illinois Retina Associates, S.C. Chicago, IL

Photodynamic therapy and other options for AMD Ophthalmic Challenges in the New Millennium Update for Anterior and Posterior Segment Surgeons Rush-Presbyterian-St. Luke's Medical Center Department of Ophthalmology, Rush Medical College Illinois Retina Associates, S.C. Chicago, IL Vitrectomy for chronic diabetic macular edema Ophthalmic Challenges in the New Millennium Update for Anterior and Posterior Segment Surgeons Rush-Presbyterian-St. Luke's Medical Center Department of Ophthalmology, Rush Medical College Illinois Retina Associates, S.C. Chicago, IL

Ophthalmic Challenges in the New Millennium Update for Anterior and Posterior Segment Surgeons Rush-Presbyterian-St. Luke's Medical Center Department of Ophthalmology, Rush Medical College Illinois Retina Associates, S.C. Chicago, IL August, 1998 Vented gas forced infusion with surgeon controlled elevated infusion ACCURUS Symposium/1998 Alcon Retinal Symposium: Advanced Surgical Techniques and Emerging Technology Napa Valley, CA

George A. Williams, M.D. Page 57 A re-appraisal of the macular vitreoretinal interface; clinical implications for enzyme- assisted vitreous surgery Ophthalmology Times Japan Symposium Tokyo, Japan Enzymatic vitrectomy Kyoto, Japan September, 1998 Closure of traumatic macular holes without adjuvants Club Jules Gonin Edinburgh, Scotland Cataract surgery in the patient with diabetes: a retinal surgeon's perspective 1998 Meeting of the Oklahoma and Arkansas Acadamies of Ophthalmology Ridgedale, MO

Retained lens fragments and dislocated intraocular lenses: Current concepts 1998 Meeting of the Oklahoma and Arkansas Acadamies of Ophthalmology Ridgedale, MO Endophthalmitis: What have we learned? 1998 Meeting of the Oklahoma and Arkansas Acadamies of Ophthalmology Ridgedale, MO

Cystoid macular edema and prevention of retinal detachment: What the anterior segment surgeon should know

1998 Meeting of the Oklahoma and Arkansas Acadamies of Ophthalmology Ridgedale, MO November, 1998 Enzymatic vitrectomy update Vitreoretinal Update 1998 American Academy of Ophthalmology Meeting 1998 New Orleans, LA Systemic therapeutic agents and retinal toxicity, course 424 American Academy of Ophthalmology Meeting 1998 New Orleans, LA

Surgery of retinal detachment, course 635 American Academy of Ophthalmology Meeting 1998 New Orleans, LA

Controversies in macular hole surgery, course 848 American Academy of Ophthalmology Meeting 1998 New Orleans, LA February, 1999 Vitrectomy for chronic diabetic macular edema Sarasota Vitreoretinal Update Sarasota, FL

Photodynamic therapy Sarasota Vitreoretinal Update Sarasota, FL Enzymatic vitrectomy Sarasota Vitreoretinal Update

George A. Williams, M.D. Page 58 Sarasota, FL

Traumatic macular holes Symposium on Ocular Trauma Henry Ford Hospital Detroit, MI March, 1999 Enzymatic Vitrectomy McGill University Montreal, Canada Spots and Dots McGill University Montreal, Canada April, 1999 Current concepts in cystoid macular edema 83rd Annual Clinical Assembly of the American Osteopathic Colleges of Ophthalmology Orlando, FL

Current concepts in subfoveal neovascularization The Retina Center Ocala, FL

Clinical trials and ongoing research at Beaumont Eye Institute Beaumont Optometric Update William Beaumont Hospital and the Beaumont Eye Institute Royal Oak, MI September, 1999 Photodynamic therapy The Vitreous Society Annual Meeting Rome, Italy October, 1999 Current concepts in thrombosis for retinal vascular disease American Academy of Ophthalmology Annual Meeting Orlando, FL

Surgery of retinal detachment American Academy of Ophthalmology Annual Meeting Orlando, FL

Controversies of macular hole surgery American Academy of Ophthalmology Annual Meeting Orlando, FL

Systemic therapeutic agents & retinal toxicity American Academy of Ophthalmology Annual Meeting Orlando, FL November, 1999 Photodynamic therapy Egyptian Vitreoretinal Society Hurgada, Egypt

Thombophilia in retinal vascular disease Eypgtian Vitreoretinal Society Hurgada, Egypt


Enzymatic vitrectomy Ain Shams University Cairo, Egypt December, 1999 Pharmacolobic manipulation of endogenous vitreous matrix metalloproteinases: implications of

vitreolysis The Retina Society Annual Meeting Maui, HI January, 2000 Surgical strategies for the management of occlusive retinal vascular disease St. Christoph Vitrectomy Meeting St. Christoph am Arlberg, Austria February, 2000 Posterior segment manifestations of blunt trauma Scientific Committee of XXIII Moacyr Alvaro International Symposium Sao Paulo, Brazil

Thrombophilia and retinal vascular disease Scientific Committee of XXIII Moacyr Alvaro International Symposium Sao Paulo, Brazil

Vitrectomy for traumatic macular holes Scientific Committee of XXIII Moacyr Alvaro International Symposium Sao Paulo, Brazil

Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin - one year results of 2 randomized clinical trials - TAP

report 1 Scientific Committee of XXIII Moacyr Alvaro International Symposium Sao Paulo, Brazil The use of enzymes in vitreous surgery Scientific Committee of XXIII Moacyr Alvaro International Symposium Sao Paulo, Brazil March, 2000 Retinal translocation in the era of photodynamic therapy Vail Vitrectomy Meeting 2000 Vail, CO May, 2000 Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular

degeneration with verteporfin Clinical Day in Ophthalmology 2000 London, Ontario, CANADA

Enzyme-assisted vitreous surgery Clinical Day in Ophthalmology 2000 London, Ontario, CANADA Current concepts of thrombosis for retinal vascular disease Clinical Day in Ophthalmology 2000 London, Ontario, CANADA Photodynamic therapy Eye MDs Seeing Into the New Millennium Mid-Atlantic Regional Meeting The Homestead

George A. Williams, M.D. Page 60 Hot Springs, VA

Cataract extraction in the diabetic patient Eye MDs Seeing Into the New Millennium Mid-Atlantic Regional Meeting The Homestead Hot Springs, VA June, 2000 Does cataract surgery exacerbate age-related macular degeneration? Top of the World Comprehensive Ophthalmology Symposium Girwood, AK

Therapeutic options for subfoveal choroidal neovascularization (CNV) Top of the World Comprehensive Ophthalmology Symposium Girwood, AK Photodynamic therapy for choroidal neovascularization (CNV) in age-related macular

degeneration, Top of the World Comprehensive Ophthalmology Symposium

Current concepts in macular hole surgery Top of the World Comprehensive Ophthalmology Symposium Girwood, AK October, 2000 Current concepts in thrombophilia for retinal vascular disease 3rd Vitreoretinal Symposium, Frankfurt-Marburg 2000 Frankfurt, Germany Vitrectomy for diabetic macular edema associated with a taut posterior hyaloid 3rd Vitreoretinal Symposium, Frankfurt-Marburg 2000 Frankfurt, Germany

Verteporfin for occult choroidal neovascularization in age-related macular degeneration:

VIP one-year results American Academy of Ophthalmology Annual Meeting Dallas, TX Controversies in macular surgery American Academy of Ophthalmology Annual Meeting Dallas, TX

Systemic therapeutic agents & retinal toxicity American Academy of Ophthalmology Annual Meeting Dallas, TX

Surgery of retinal detachment

American Academy of Ophthalmology Annual Meeting Dallas, TX

January, 2001 Verteporfin for occult choroidal neovascularization in age-related macular degeneration: VIP one-year results

The Vitreous Society Annual Meeting Cancun, Mexico

Retinal relativity The Vitreous Society Annual Meeting Cancun, Mexico

George A. Williams, M.D. Page 61 February, 2001 Photodynamic therapy for choroidal neovascularization Midwinter retinal symposium Medical College of Wisconsin Milwaukee, WI

Alternative treatments for choroidal neovascularization Midwinter retinal symposium Medical College of Wisconsin Milwaukee, WI March, 2001 Enzymatic vitreous surgery for occlusions Advanced Vitreoretinal Course Antwerp, Belgium Vitrectomy for chronic and traumatic macular holes Advanced Vitreoretinal Course Antwerp, Belgium

Submacular Surgery Trial (SST) Update Advanced Vitreoretinal Course Antwerp, Belgium

Expanded indications of photodynamic therapy Advanced Vitreoretinal Course Antwerp, Belgium Retinal translocation in the photodynamic therapy-era Advanced Vitreoretinal Course Antwerp, Belgium

Vitrectomy for diabetic macular edema Advanced Vitreoretinal Course Antwerp, Belgium April, 2001 Options and Controversies and New Developments in Vitreoretinal Disease and Surgery Cleveland Clinic Cleveland, OH June, 2001 The role of ILM peeling in macular hole surgery Southwest Vitreoretinal Symposium San Antonio, TX Current concepts in pharmacologic vitreolysis Southwest Vitreoretinal Symposium San Antonio, TX Vitrectomy for diabetic macular edema Southwest Vitreoretinal Symposium San Antonio, TX Photodynamic therapy (PDT) for occult CNV Southwest Vitreoretinal Symposium San Antonio, TX Macular translocation in the PDT era

George A. Williams, M.D. Page 62 Southwest Vitreoretinal Symposium San Antonio, TX July, 2001 Treatment options in choroidal neovascularization New Mexico Academy of Ophthalmology Santa Fe, New Mexico Management of dislocated lens fragments and intraocular lenses New Mexico Academy of Ophthalmology Santa Fe, New Mexico

Cataract formation in diabetes New Mexico Academy of Ophthalmology Santa Fe, New Mexico September, 2001 Current Concepts in Vitreoretinal Enzymes

31st Brazilian Congress San Paulo Brazil New Therapeutic Options for Age-Related Macular Degeneration

31st Brazilian Congress San Paulo Brazil November, 2001 Controversies in Macular Surgery

American Academy of Ophthalmology Annual Meeting New Orleans, LA Surgery of Retinal Detachment American Academy of Ophthalmology Annual Meeting New Orleans, LA

OTAC Symposium - Separating Fact from Fiction American Academy of Ophthalmology Annual Meeting New Orleans, LA Systemic Therapeutic Agents and Retinal Toxicity American Academy of Ophthalmology Annual Meeting New Orleans, LA

Pars Plana Vitrectomy for Diabetic Macular Edema American Academy of Ophthalmology Annual Meeting New Orleans, LA Macular Degeneration, Pure Pharmacologic Manipulation The 19th Annual Vitreous Society Meeting San Juan, Puerto Rico

Macular Degeneration, Focal Laser and TTT

The 19th Annual Vitreous Society Meeting San Juan, PR

January, 2002 Optic Neurotomy for CRVO. Zermatt St-Christoph Vitrectomy Meeting Zermatt, Switzerland Current Concepts in Management of Diabetic Macular Edema. Cincinnati Society of

Ophthalmology


Cincinnati, OH Therapeutic Options in Age-Related Macular Degeneration. Cincinnati Society of Ophthalmology Cincinnati, OH

March, 2002 Diabetic Macular Edema. Sixth Congress of Spanish Vitreoretinal Society

San Sebastian, Spain Current Concepts in Intravitreal Enzymes. Sixth Congress of Spanish Vitreoretinal Society

San Sebastian, Spain April, 2002 Macular hole Surgery.

Frankfurt Retina Meeting, Frankfurt Germany.

May, 2002 The Role of ILM Peeling in Macular Hole Surgery Duke 13th Advanced Vitreous Surgery Course Durham, NC Management of Traumatic and Chronic Macular Holes Duke 13th Advanced Vitreous Surgery Course Durham, NC Current Concepts in Pharmacologic Vitreolysis Duke 13th Advanced Vitreous Surgery Course Durham, NC Current Concepts in Vitrectomy for Diabetic Macular Edema Duke 13th Advanced Vitreous Surgery Course Durham, NC Photodynamic Therapy: Is It Really That Bad? Duke 13th Advanced Vitreous Surgery Course Durham, NC June, 2002 Current Concepts in Diabetic Macular Edema

Intravitreal Enzymes Canadian Ophthalmological Society Montreaux, Quebec

August, 2002 Retinopathy of prematurity Michigan Ophthalmological Society Annual Meeting Mackinac Island, MI Vitrectomy for chronic macular holes 23rd Congress of the Club Jules Gonin Montreux, Switzerland September, 2002 Long-term results of scleral buckling for primary repair of rhegmatogenous retinal detachment. Retina Congress San Francisco, CA Long-term results of scleral buckling for primary repair of rhegmatogenous retinal detachment. Retina Congress

George A. Williams, M.D. Page 64 San Francisco CA October, 2002 Photodynamic therapy for AMD: Practical concerns, economics and satisfaction. American Academy of Ophthalmology Annual Meeting Orlando, FL Management of vein occlusions American Academy of Ophthalmology Annual Meeting Orlando FL Systemic medications and retinal toxicity Instruction course American Academy of Ophthalmology Annual Meeting Orlando, FL Visual results following pars plana vitrectomy for retained lens fragments Discussion American Academy of Ophthalmology Annual Meeting Orlando, FL Controversies in macular surgery American Academy of Ophthalmology Annual Meeting Orlando, FL

RhuFab V2 (anti-VEGF antibody) for treatment of exudative AMD Discussion American Academy of Ophthalmology Annual Meeting Orlando, FL

Adult retinopathy of prematurity and hereditary vitreoretinopathies

American Academy of Ophthalmology Annual Meeting Orlando, FL

Surgery of retinal detachment Course American Academy of Ophthalmology Annual Meeting Orlando, FL

Photodynamic Therapy for AMC: Practical concerns, economics and satisfaction American Academy of Ophthalmology Orlando, FL

Management of vein occlusions American Academy of Ophthalmology Orlando, FL Instruction Course: Systemic medications and retinal toxicity American Academy of Ophthalmology Orlando, FL Visual results following pars plana vitrectomy for retained lens fragments American Academy of Ophthalmology Orlando, FL Controversies in macular surgery American Academy of Ophthalmology

George A. Williams, M.D. Page 65 Orlando, FL RhuFab V2 (anti-VEGF antibody for treatment of exudative AMD American Academy of Ophthalmology Orlando, FL Adult retinopathy of prematurity and hereditary vitreoretinopathies American Academy of Ophthalmology Orlando, FL Surgery of retinal detachment Course Presenter American Academy of Ophthalmology Orlando, FL January, 2003 Current concepts in diabetic macular edema Photodynamic Therapy Squaw Valley, Retina Symposium Squaw Valley, CA May 1, 2003 Therapeutic Options in Choroidal Neovascularization 87th Annual Clinical Assembly of the American Osteopathic Colleges of Ophthalmology and

Otolaryngology-Head and Neck Surgery foundation, Inc. Sanibel Island, FL May 4-8, 2003 Efficacy of free plasmin and streptokinase-plasmin complex in the degradation of fibronectin

and laminin Treatment of persistent macular edema (PME) associated with uveitis or Irvin-Gass syndrome

(IGS) with an intravitreal bioerodible sustained dermethasone release. Photoreceptors and photopigments in fossorial rodent, the pocket gopher (Geomys bursarius) An intravitreous dexamethasone bioerodible drug delivery system for the treatment of persistent

diabetic macular edema. Treatment of persistent macular edema associated with central and branch retinal vein occlusion

with extended delivery of intravitreal dexamethasone. Association for Research in Vision and Ophthalmology (ARVO) Fort Lauderdale, FL July 5, 2003 New Horizon in Vitreoretinal Pharmacology,

Pisa, Italy August, 2003 A comparison of visual acuity, contrast sensitivity, fluorescein angiography and OCT in the

treatment of persistent macular edema. 21st Annual Meeting of the American Society of Retina Specialists New York September, 2003 Treatment of persistent macular edema associated with retinal venous occlusive disease with

Dexamethasone implant. 36TH scientific Session of The Retina Society Chicago, IL October, 2003 A systematic approach to diabetic macular edema Photodynamic Therapy is it really that bad?

George A. Williams, M.D. Page 66 Retinal Relativity Update on screening for diabetic retinopathy A randomized controlled trial of a Dexamethasone Intravitreal bioerodable implant for persistent

macular edema 3rd Annual Southwest Vitreoretinal Symposium San Antonio, TX November, 2003 A Systematic Approach to Diabetic Macular Edema Moorfields Eye Hospital, London, England

Pharmacologic Vitreolysis The Royal Liverpool and Broadgreen University Hospitals Liverpool, England Management of Retinal Venous Occlusions: A New Era British and Eyre Vitreoretinal Society (BEVRS) 2003 Annual Meeting Telford Moat House, Telford, England

January, 2004 Systemic Approach to Diabetic Macular Edema Connecticut Society of Eye Physicians Plantsville Connecticut So You’re A Retina Doc….Now What? 2004 Fellows’ Forum Chicago, IL February, 2004 Five-Year Results of Verteporfin Photodynamic Therapy in Pathologic Myopia: Third year of an

Open Label Extension of the VIP Trial. The Macula Society Meeting Las Vegas, nv April, 2004 Results of Radial Optic Neurotomy for Central Retinal Vein Occlusion Diabetic Traction Retinal detachment (20-Gauge Vitrectomy) Removal of Lipid Exudates in Diabetic Retinopathy Drug Treatment, Diabetic Retinopathy

Frankfurt Retina Meeting Frankfurt, Germany

Current management of retinal venous disease

A systematic approach to diabetic macular edema 3rd Retina-Macula, Vitreous Hippocratic Symposium Thessaloniki – Halkidiki Greece August, 2004 Breakfast with the Masters: Macular Hole – Improving your Results

Combined Radial Optic Neurotomy and Intravitreal Triamcinolone for Central Venous Vein Occlusion 22nd Annual ASRS Meeting San Diego, CA

September, 2004 Combined Radial Optic Neurotomy and Intravitreal Triamcinilone for Central Retinal Vein

Occlusion XXIVth Meeting of the Club Jules Gonin Vouliagmeni, Athens Greece

George A. Williams, M.D. Page 67 October, 2004 Course, The Expanding Role of Pars Plana Vitrectomy in the Treatment of Primary

Rhegmatogenous Retinal detachment. Instruction Course: Surgery and Retinal Detachment Presentation: Treatment of Inflammatory Macular Edema with a Dexamethasone Posterior

Segment Drug Delivery System Breakfast with the Experts: Management of Retinal Vascular Occlusions Moderator: Instruction Course: Systemic Therapeutic Agents and Retinal Toxicity Symposium: Macular Holes: The Latest in Current Management. Twenty Years of Progress in the

Treatment of Retinal Diseases: Where We Have Been, Where We are Now and Where We Will Be

American Academy of Ophthalmology Annual Meeting New Orleans, LA November, 2004 A Systemic Approach to Diabetic Macular Edema Management of Central Venous Vein Occlusion XXV Ophthalmology Congress Belo Horizonte, Brazil Is Age-Related Macular Degeneration a Surgical Disease? Advanced Retinal Therapy Meeting Vienna, Austria February, 2005 Issues in Reimbursement in the Era of Pharmacology for AMD Treatment of Inflammatory Macular Edema with Dexamethasone Posterior-Segment Drug

Delivery System (Posurdex) March, 2005 The Macula Society Meeting Key Biscayne Florida

New Treatments for Diabetic Maculopathy Invited speaker, Moorfields Bicentenary Meeting London, England April, 2005 Socio-Economic Implications of Age-Related Macular Degeneration Innovations in ARMD Therapy 2005: Integrating Emerging Therapies into Clinical Practice Boston, MA May, 2005 Emerging Therapies and Administration Techniques Radial Optic Neurotomy

Retinal Physicians 2005 Symposium: Current Concepts in Retina Medicine Atlantis, Bahamas

July, 2005 Macular Holes – To Peel or Not to Peel Breakfast with the Experts Instructional course: Retinal Coding: Update 2005

American Society of Retina Surgeons Montreal, Canada September, 2005 Changing Strategies in the Management of Neovascular Age-related Macular Degeneration Panel Discussion The Retina Society Coronado, CA October, 2005 Instructor Course: Systemic Therapeutic Agents and Retinal Toxicity

Instructor Course: The Expanding role of Pars Plana Vitrectomy in the Treatment of Primary Rhegmatogenous Retinal Detachment. Instructor Course: Surgery of Retinal Detachment


American Academy of Ophthalmology Annual Meeting Chicago, IL

November, 2005 The Indications for 25 Gauge Elective Vitrectomy National Congress of Ophthalmic Surgery 25 Gauge Symposia Milan, Italy December, 2005 New Technology for Intravitreal Drug Delivery Portuguese Society of Ophthalmology Cascais, Portugual January, 2006 Legal Implications of Avastin use for AMD

Macula 2006: New York February, 2006 Economic and Legal Implications of Anti-VEGF Therapies Angiogenesis 2006 Bascom Palmer

Miami, FL Diabetic Retinopathy and Vascular Occlusive Diseases Ocular Pharmacology World Ophthalmology Congress: 2006 Sao Paulo, Brazil March, 2006 Safety and Efficacy of an Intravitreal Dexamethasone Biodegradable Drug Delivery System for

the Treatment of Persistent Macular Edema Autologous Plasmin for all that Ails You. A Comparison of Applicator vs. Incisional Placement of the Dexamethasone Sustained-Release

Drug Delivery System 6th International Symposium of Ocular Pharmacology and Therapeutics (ISOPT)

Berlin, Germany April, 2006 Economic Implications of AMD American Academy of Ophthalmology Mid-Year Forum Washington, DC

Vitrectomy for Vitreomacular Traction Syndromes Intravitreal Avastin Injection: Short-Term Results and Potential Complications

Frankfurt Retina Meeting: 2006 Frankfurt, Germany May, 2006 Update on Small Gauge Vitreoretinal Surgery AVTT Symposium

Scleral Buckle with Pars plana Vitrectomy vs. Scleral Buckle Alone in Pseudophakic Retinal Detachment Atypical Presentations of Progressive Outer Retinal Necrosis Masked by Pre-Existing Non-HIV Related Co-Morbidities. Macugen as Primary Therapy for AMD Lesions of All Angiographic Subtypes. Efficacy and Safety of a Novel Intravitreous Dexamethasone Drug-Delivery System After Applicator or Incisional Placement in Patients With Macular Edema. ARVO 2006 Annual Meeting Ft. Lauderdale, FL

May, 2006 Will the Wait be Worth It? Results from the Lucentis Trials in Neovascular AMD

George A. Williams, M.D. Page 69 Current Controversies in the Management of Retinal Disease 2006. Presented by Associated Retinal Consultants

Detroit Institute of Arts Detroit, MI

June, 2006 Management of Traumatic and Chronic Macular Hole Current Macugen Concepts 2006 Pharmacologic Vitreolysis: 2006 VII International Symposium on Ocular Trauma Rome, Italy July, 2006 Current Concepts in the Management of Traumatic Macular Hole VII International Symposium on Ocular Trauma Rome Italy August, 2006 Retinal Relativity 23 Gauge Vitrectomy Surgery The Bridge Study Legal Issues in Off Label Drug Usage Advanced Vitreoretinal Technology and Therapies Chicago, IL September, 2006 A New 23-Gauge Vitrectomy System American Society of Retina Specialists Cannes, France Current Concepts in Neovascular AMS New England Ophthalmological Society Harvard University Boston, MA October, 2006 Foveal Dysplasia Evident by Optical Coherence Tomography in Patients with a History of

Retinopathy of Prematurity A New 23 Gauge Vitrectomy System The Retina Society and Club Jules Gonin Cape Town, South Africa November, 2006 Legal Issues Re: Off Label Drug Use.

Evaluation of an Intravitreous Dexamethasone Drug Delivery System in Patients with Persistent Diabetic Macular Edema

Summary: Economic impact of therapy for retinal vascular disease on physician and Society American Academy of Ophthalmology Annual Meeting Las Vegas, NV

January, 2007 The Future of Physician Payment Current Concepts in AMD Retinal Update 2007 Minneapolis, MN February, 2007 Current Concepts in the Management of Neovascular Age-Related Macular Degeneration

2007 Angiogenesis Bascom Palmer Eye Institute Miami, FL

March, 2007 Those Were the Days, My Friend Vail Vitrectomy-2007

George A. Williams, M.D. Page 70 Vail, CO May, 2007 Unmet Needs and New Drug Opportunities in Treating Retinal Disease Laser vs. Pharmacology: Which One to Choose? ARVO 2007 Fort Lauderdale, FL Lucentis in Neovascular AMD: Subgroup Analysis of First Year Efficacy Data From the PEIR

Study. The Macula Society 30th Annual Meeting London, England

June, 2007 Keynote address: Age-related macular degeneration: The odds are improving OSN Las Vegas: Improving Your Odds 2007 Las Vegas, NV September, 2007 25 gauge, 23 gauge or 20 gauge instrumentation for vitreous surgery? 37th Cambridge Ophthalmological Symposium Cambridge, England Neuroprotection: the next frontier in retinal disease REACT 2007 Meeting Kyoto Japan Neuroportection: A new era drawing? New steroid delivery systems and experience with a new 23 gauge vitrectomy system. Advanced Vitreous Surgery Course Tokyo, Japan October 2007 The Future of Physician Reimbursement

Nashville Academy of Ophthalmology The New Horizon in Retinal Pharmacology Vanderbilt University School of Medicine Nashville, TN

November, 2007 The Economics of Bevacizumab vs. Ranibizumab Intravitreal Medical Therapy for Diabetic Retinopathy Pay for Performance and Other Policy Updates for 2008 and

Beyond and a Guide to FDS Ophthalmic Drug and Device Evaluation. The Health Care Industry: Who Profits and Who Pays? American Academy of Ophthalmology Annual Meeting New Orleans, LA Course Instructor: Medical and Surgical Retina Coding: From Angiograph to Vitrectomy and Every Case in Between. Surgery of Retinal Detachment Systemic Therapeutic Agents and Retinal Toxicity

December, 2007 The Times They Are a Changing. 25th Annual American Society of Retina Specialists Meeting

Indian Wells, CA January, 2008 Retinal Neuroprotection The Era of Retinal Pharmacology Atlantic Coast Retina Meeting

George A. Williams, M.D. Page 71 Wills Eye Hospital Philadelphia, PA February, 2008 Medicare Part B Drugs: An Unsustainable Model Angiogenesis, Exudation and Degeneration 2008

Key Biscayne, FL Gifford Lecture: Physician Reimbursement: Past, Present and Future Retinal Neuroprotection: The Next Frontier IAO/COS 2008 Joint Clinical Conference, Rosemont, IL March, 2008 The Future of Physician Reimbursement Retinal Neuroprotection: The Next Frontier Aspen Retinal Detachment Society Meeting Snowmass, CO May, 2008 Retinal Neuroprotection 8th Euretina Congress Vienna, Austria June, 2008 Current Concepts in Retinal Neuroprotection 3rd Mediterranean Retina Meeting Istanbul, Turkey The Future of Medicare Kresge Eye Institute’s 53rd Annual Clinical Conference Troy, MI Ocular Drug Delivery to the Posterior Segment Session Steroid Implants Microplasmin in Vitrectomy Debate: For: Posturing is Necessary after Macular Hole Surgery Update in Diabetic Retinopathy panelist Pharmacologic Therapy for PVD Retinal Vascular Occlusion: Novel Strategies World Ophthalmology Congress Hong Kong August, 2008 What is RUC? New Issues in Retinal Coding The Healthcare System – Who Profits, Who Pays? Posurdex Dexamethasone Implant and other Sustained-Release Corticosteroid Implants Retinal Neuroprotection Advanced Vitreoretinal Techniques & Technology (AVTT) Symposium Chicago, IL October, 2008 Initial Management of Choroidal Neovascularization: Visual Acuity and Quality of Life Evidence Management of AMD Mini-Symposium Troy, MI Enzymatic Vitreolysis Retinal Neuroprotection 15th Anniversary Meeting at The Retina Center Pali Momi


Oahu, HI The Office as Dispensary: Managing Drug Inventory and Accounting Megatrends in Vitreoretinal Practice: Where Do the AAO and the ASRS Fit In? 26th ASRS – Breakfast with the Masters Wailea, HI Age-Related Macular Degeneration Royal Oak Public Library Royal Oak, MI November, 2008 US Perspective on Shared Care Spots and Dots New Concepts in Neuroprotection for the Treatment of Retinal Disease Avastin vs Lucentis – the US Perspective Panelist on AMD Update Laser vs Pharmacotherapy for Diabetic Eye Disease Panelist on Guidance for Clinical Use of Lucentis Panelist for Cataract Surgery: The Big Picture New Concepts in Pharmacologic Vitreolysis Anti-VEGF and Retinal Disease The Royal Australian and New Zealand College of Ophthalmologists Conference (RANZCO) Melbourne, Australia Retina Coding Update Pharmaceuticals in Ophthalmology: What Do We Need and What Can We Afford? Overview of Neuroprotection Issues in Retinal Coding and Reimbursement American Academy of Ophthalmology

Atlanta, GA January, 2009 New Concepts in Retinal Neuroprotection Atlantic Coast Retinal Club – Macula 2009 New York, NY Neuroprotection in AMD Macula of Paris Paris, France March, 2009 Laser Surgery for Macular Edema Intraocular Surgery for Macular Edema Vitreolysis for Diabetic Macular Edema Microplasmin for Vitreomacular Traction Retinal Neuroprotection MEACO 2009 Bahrain April, 2009 Retinal Neuroprotection Enzymatic Vitreolysis University of Louisville, KY May, 2009 New Advances in Vitreoretinal Surgery Enzymatic Vitreolysis Controversies in Small Gauge Vitrectomy EURETINA 2009

George A. Williams, M.D. Page 73 Nice, France September, 2009 European School for Advanced Studies in Ophthalmology Diabetic Retinopathy Diabetic Macular Edema

Lugano, Switzerland

October, 2009 American Academy of Ophthalmology Pan-American Academy of Ophthalmology Ciliary Neurotrophic Factor for Dry AMD & Retinal Degeneration Panel Discussion Re: The Management of a Delayed Bag-IOL Dislocation and Whether to Suture the IOL or Replace it Medications and Retinal Toxicity Other Experimental Pharmacotherapies for DME Costly & Common Retina Coding Errors San Francisco, CA January, 2010 Follow the Money: What You Need to Know About Balance Sheets, Accounts, and the Finance Department

AUPO Sarasota, FL February, 2010 Healthcare Economics 101

Kresge Eye Institute Detroit, MI March, 2010 Retinal Neuroprotection Enzymatic Vitreolysis

Duke University Eye Center Durham, NC Intravitreal Brimonidine Implant for Retinal Apoptosis

2010 Vail Vitrectomy Meeting Vail, CO April, 2010 New Pharmacologic Vitreolysis with Microplasmin New Pharmacologic Treatments for Retinal Disease

114th Annual Meeting of the Japanese Ophthalmological Society Nagoya, Japan May, 2010 Health care reform: What determines our fate?

65th Annual Oregon Ophthalmological Alumni Association Casey Eye Institute Portland, OR Progression of diabetic retinopathy and age-related macular degeneration follow cataract surgery

Current Controversies in the Management of Retinal Disease 2010 Auburn Hills, MI Endophthalmitis

2nd Annual Detroit Regional Ophthalmology Interchange Royal Oak, MI July, 2010 Laser & Surgery: What is on the horizon?

ARVO 2010 Summer Eye Research Conference

George A. Williams, M.D. Page 74 National Institute of Health, National Eye Institute Bethesda, MD August, 2010 What happened to healthcare reform?? MiSEPS Annual Conference Mackinac Island, MI October, 2010 Neuroprotection for Geographic Atrophy and Retinal Degenerations

Senior Instructor, Course Number 617: Surgery of Retinal Detachment Symposium Chair, What is the Preferred Method of Management of Primary Rhegmatogenous Retinal Detachment: Point, Counterpoint Retina SubSpecialty Day, Break with the Experts: V09 Retinal Coding and Reimbursement Joint Session with the Middle East Africa Council of Ophthalmology (MEACO) Symposium Chair, Current Concepts in the Management of Complicated Retinal Detachment American Academy of Ophthalmology Retina 2010: A Panretinal Perspective Chicago, IL November, 2010 A Phase 2 Study of Encapsulated Ciliary Neurotrophic Factor (CNTF) Secreting Cell Implant (NT-501) for geographic atrophy associated with AMD XXVIIth Meeting of the Club Jules Gonin Kyoto, Japan CPT and RBRVS 2011 Annual Symposium Chicago, IL December, 2010 Microplasmin for vitreomacular traction Retinal Neuroprotection Health Care Reform 2011 The Eye Center of Columbus Conference & Annual Meeting Columbus, OH Retinal Neuroprotection The Twelfth Annual Arthur Gerard DeVoe Lectureship Columbia University Edward S. Harkness Eye Institute New York, NY January, 2011 New Chairs Workshop Incentives: What type and do they work? 45th AUPO Annual Meeting

Scottsdale, AZ March, 2011 The Macula Society Boca Raton, FL May, 2011 Encapsulated cilary neurotrophic factor (CNTF) - secreting cell implant for the treatment of geographic atrophy associated with dry AMD 11th Euretina Congress London, England June, 2011 Neuroprotection Givre, Italian Society of Vitreoretinal Surgery

Annual Italian Vitreoretinal Society Meeting Rome, Italy

George A. Williams, M.D. Page 75 July, 2011 Retinal Neuroprotection

Combination laser therapy with intravitreal ranibizumab: the DRCR.net protocol I Hot topics in VR surgery XXIX Pan American Congress of Ophthalmology (PAAO) Buenos Aires, Argentina

July, 2011 Plasmin, Implants and Inserts Surgical Pharmacology for Vitreolysis and Neuroprotection

2nd Annual Massachusetts Eye & Ear Vitrecomy Course Boston, MA

August, 2011 What have we learned from the CATT-How has it impacted my practice, and will it affect financial reimbursement? Discussing therapeutic options with patients Vitreomacular traction and macular hole-the Microplasmin update 11th Annual Advanced Vitreoretinal Techniques & Technology (AVTT) Symposium & CPE Vitreoretinal Fellow’s Program Chicago, IL August, 2011 29th Annual Meeting, American Society of Retinal Surgeons (ASRS) Boston, MA August, 2011 Pharmologic Vitreolysis

Mid Year Seminar for Osteopathic Ophthalmologists Detroit, MI

October, 2011 Presenter, Subspecialty Day Surgery by Surgeons Surgery of Retinal Detachment, Instructor Systemic Therapeutic Agents and Retinal Toxicity, Instructor Symposia Chair Symposia Presenter Diabetic Macular Edema: 2011 Update on Management, Instructor American Academy of Ophthalmology Retina 2011: The Magical World of Retina Orlando, FL February, 2012 The effect of cataract surgery on diabetic retinopathy and age-related

macular degeneration Neovascular AMD 2012; CATT’s and Traps Which drug for which patient? Wisconsin Eye MD Symposium Milwaukee, WI

March, 2012 Health Care Reform Retinal Neuroprotection Aspen Retinal Detachment Society (ARDS) Snowmass, CO May, 2012 Novel Therapeutic Targets for Diabetic Retinopathy Symposium

ARVO Ft. Lauderdale, FL

June, 2012 Innovations in vitreoretinal surgery (dry AMD-NTGF implant) Keynote Lecture


25th International Congress of German Ophthalmic Surgeons Nuremberg, Germany

August, 2012 Ophthalmic Workforce, Physician Productivity and the Economics of Vitreoretinal Practice What is the RUC? And New Issues in Retinal Coding Follow the Money: Physician Payment Models

12th Annual Advanced Vitreoretinal Techniques & Technology (AVTT) Symposium & CPE Vitreoretinal Fellow’s Program Chicago, IL August, 2012 Panelist for Vitreoretinal Surgery Challenges Symposium Retinaws Course

30th Annual Meeting, American Society of Retinal Surgeons (ASRS) Las Vegas, NV September, 2012 Main Session 2 PVR & Retinal Detachment

Ciliary Neurotrophic Factor Presentation Chair, Neovascular AMD Session 12Euretina Congress Milan, Italy

November, 2012 Co-Presenter, Meet the Expert Session November, 2012 Co-Chair Session 6: Disorders of the vitreomacular interface Presenter, Session 6: Surgical approaches to abnormalities of the vitreomacular interface ESASO 12th International AMD & Retina Congress Prague. Section II: Non-neovascular AMD

Break With The Experts Business of Retina Advanced Vitreoretinal Surgical Techniques and Instrumentation Retina Pearls for the Anterior Segment Surgeon Diabetic macular Edema: 2012 Update on Management Video Case Presentations of Retina and Vitreoretinal diseases State of the Art Techniques and Technologies How to Treat Complex Vitreoretinal Diseases Systemic Therapeutic Agents and Toxicity Surgery of Retinal Detachment American Academy of Ophthalmology Annual Meeting Chicago, IL.

January, 2013 Time/Life Management: Tips from the front lines

Presentation: The Big World of Medicine & Governmental Affairs Managing the Department: Skills for Chairs Workshop

Incentives: What Type and Do They Work? 47th Annual AUPO Meeting Loews Coronado Bay San Diego, CA February, 2013 Macula Society Dana Pointe, CA March, 2013 Symposium 7: Retinal Detachment II & Peds

The Mechanism of Persistent Subretinal Fluid after Retinal Detachment Surgery Vail Vitrectomy

George A. Williams, M.D. Page 77 Vail, CO April, 2013 Viewpoint from a Financial Perspective – Does it Make Good Business and Practice Sense? Annual Mid-Year Forum Washington, DC June, 2013 ESASO Lugano, Switzerland August, 2013 25TH Annual Midwest Ocular Angiography Conference (MOAR) St. Andrews, Scotland

Pan American Congress of Ophthalmology (PAAO) XXXVII Congress Rio de Janeiro, Brazil

Advanced Vitreoretinal Techniques & Technology (AVTT) Symposium Chicago, IL Pharmacologic Vitreolysis: Past, Present and Future 30th Annual ASRS Toronto, Canada November, 2013 Instructor: Systemic Therapeutic Agents and Retinal Toxicity, Course 602

Management of Vitreoretinal Interface Diseases, Event No. SYM38 Enzymatic Management of Abnormalities of the Vitreomacular Interface Diabetic Macular Edema: 2013 Update on Management, Course 339 Advanced Vitreoretinal Surgical Techniques and Instruments, Course 392 American Academy of Ophthalmology Annual Meeting, New Orleans, LA

December, 2013 Best of Retina 2013 New York, NY

April, 2014 Retina Subspecialty Day

Speaker, Session 1250 Diseases of the Vitreomacular Interface Speaker, Session 1251 Vitreomacular Interface Reloaded for Interaction World Ophthalmology Congress (WOC) of the International Council of

Ophthalmology: 2014 Tokyo, Japan Moderator, Opening Session – From Volume to Value: Finding Balance in a Changing

Reimbursement Landscape American Academy of Ophthalmology Mid-Year Forum Washington, DC June, 2014 Wang Wong Memorial Lecture Keynote Speaker Health Care Reform 2014 10th Annual Resident and Alumni Day Rush University Chicago, IL July, 2014 Presenter: New Payment Methods for Physicians

George A. Williams, M.D. Page 78 What is the RUC? New Issues in Retinal Coding Audits: Here, There and Everywhere Retinal Techniques for IOL Repositioning and/or Replacement Adult ROP Advanced Vitreoretinal Techniques & Technology (AVTT) Symposium Chicago, IL August, 2014 Moderator, Socioeconomic Panel Moderator, Socioeconomic Symposium American Society of Retina Specialists (ASRS) Annual Meeting San Diego, CA New Developments in Retina/Challenging Imaging Cases What’s new in surgical techniques? (Management of dislocated PC IOLs) Nordic Congress 2014 Stockholm, Sweden October, 2014 Speaker, Current concepts in pharmacologic vitreolysis Speaker, Retinal coding 2014: Dollars and Sense Moderator, Surgical Retina Retina Update and Case Conference Mayo Clinic Rochester, MN November, 2014 Instructor: Advanced Vitreoretinal Surgical Techniques, Course E451A

Systemic Therapeutic Agents and Retinal Toxicity, Course S106B Surgery of Retinal Detachment, Course N138 Section III: Business of Retina American Academy of Ophthalmology Annual Meeting, Chicago, IL

February, 2015 38th Annual Macula Society Meeting Scottsdale, AZ April, 2015 Comprehensive Ophthalmology Pearls XVIII Symposium Management of Dislocated IOLs Nashville, TN April, 2015 Presenter, Subspecialty/Specialized Interest Section Meeting RUC Surveys & Misvalued Codes Targets Opening Session - Under Pressure: Payment Trends in the Insurance Marketplace Hearing 1B - Ophthalmic Pharmaceuticals: New Challenges to Access Mid Year Forum Washington, DC May, 2015 Chicagoland Midwest Retina Update 5th Meeting Health Care Reform 2015: Dollars and Sense Chicago, IL August, 2015 47th Annual Conference of the Michigan Society of Eye Physicians and Surgeons (MiSEPS) Health Care Reform 2015: Dollars and Sense OMIC Mackinac Island, MI August, 2015 15th Annual Advanced Vitreoretinal Techniques & Technology Symposium (AVTT)

George A. Williams, M.D. Page 79 Alternative Payment Models and What the RUC is Happening with Surgical Payments? Audits: Here, There and Everywhere Retinal Techniques for IOL Implantation and Re-Positioning The Economics of Intravitreal Injections Primary Vitrectomy Surgery Remains the Treatment of Choice Adult ROP update Predicting anti-VEGF response Chicago, IL November, 2015 Presenter: RET05 Can it Be Less? Strategies for Reducing the Cost of Health Care Instructor: 223 Managing the Dislocated IOL Poster Co-Author: PO248 Wide Field Angiography in Patients without Peripheral Disease: A Study of Normal Peripheral Findings SYM 25: What Have We Learned from the IRIS Registry? Real World Lessons from the IRIS

Registry Instructor: Course 522 Surgery for Retinal Detachment in the Modern Era Presenter: Symposia SYM42 Con

American Academy of Ophthalmology Annual Meeting, Las Vegas, NV

December, 2015 Panelist: Bidirectional Flow of Data: Meaningful Quality Improvement Horizon Government Affairs

Chicago, IL Main Session: Vitreomacular traction and macular hole Case Presentations FLOREtina 2015 – Cutting Edge Live Surgery, Imaging and Innovative Science Florence, Italy

February, 2016 Presenter: Adult ROP Vail Vitrectomy Annual Meeting Vail, CO March, 2016 PIAA Governance Roundtable Scottsdale, AZ April, 2016 Mid Year Forum Promoting Eye Health Care Equity BOT/COS Responder Washington, DC June, 2016 6TH Annual Steven M. Podos, MD Symposium and Lecture: Innovations in Ophthalmology

NYEE – Mt. Sinai New York, New York Grand Canyon regional Ophthalmology Meeting

Arizona Ophthalmological Society Flagstaff, AZ July, 2016 XXXth Meeting of the Club Jules Gonin Bordeaux, France

Presenter: The Economics and Epidemiology of Intravitreal Injections IRIS: The Power of Big Data Georgia Society of Ophthalmology Hilton Head Island, SC

George A. Williams, M.D. Page 80 August, 2016 American Society of Retina Specialists (ASRS) San Francisco, CA Rochester, NY 16th Annual Advanced Vitreoretinal Techniques & Technology (AVTT) Chicago, IL September, 2016 49th Annual Retina Society Meeting San Diego, CA October, 2016 American Academy of Ophthalmology Annual Meeting November, 2016 AMA CPT and RBRVS Annual Symposium

Chicago, IL

December, 2016 UCSF Ophthalmology Update San Francisco, CA Rabb Retina Society Meeting Chicago Ophthalmological Society (COS) Quarterly Meeting Chicago, IL January, 2017 Moderator, Symposium: New Payment Models and Ophthalmology

51st AUPO Annual Meeting San Diego, CA

February, 2017 Guest Speaker: BOSTON Retina and Uveitis Network (BRUIN) Boston, MA April, 2017 Presenter: Tips and Tricks for Intrascleral PCIOL Fixation, Retinal Malpractice: The OMIC Experience

20th Advanced Vitreous Surgery (AVS) Course Duke University Durham, NC Panelist: Session 4: Complications Speaker, Session 6: New Perspectives, Stuck in the Sclera Vit Buckle Society V Las Vegas, NV August, 2017 Presenter: ACA, MACRA, MIPS, DJT: Good, Bad, and the Ugly, The IRIS Registry: Game Changer or Gimmick? 3D Heads Up Surgery Tips and Tricks for Scleral Fixation of IOLs in Combination with PPV Surgery A Paradigm Change Still Just a Research Tool and the Present Time Advanced Vitreoretinal Techniques & Technology, 16th Annual Symposium Chicago, IL November, 2017 Presenter: RET03-Retinal Detachment Outcomes IRIS Expert Discussant RET11: Business of Retina Symposia Presenter: SYM03-New Insights in Retina

George A. Williams, M.D. Page 81 Symposia Presenter: SYM62-Academy Secretary for Federal Affairs

Poster Co-Author PO250-Management and Outcomes of Subretinal Hemorrhage Associated with Retinal Arterial Macroaneurysms

Poster Co-Author PO189-Real WorldVision in AMD Patients Treated with Bevacizumab, Ranibuzumab or Afilbercept Only Over 1 Year in the IRIS Registry

Instructor: 239-Surgery for Retinal Detachment in the Modern Era Symposia Presenter: SYM30-Physician Quality Reporting: The Utility of the IRIS Registry in

Academic and Private Practice Symposia Presenter: SYM30-The Role of Advocacy in shaping the Future of Health Care Policy Presenter: Why Take the Risk? Mitigating Malpractice Risk with Patient Education and Informed

Consent Instructor: 505-Current Management of Diabetic Retinopathy and Future Directions: 2017 Update

Instructor: 544-3-D Course on Heads Up Vitreoretinal Surgery Instructor: 680-Systemic Therapeutic Agents and Retinal Toxicity Annual American Academy of Ophthalmology Meeting New Orleans, LA Wilmer Eye Institute’s 30th Annual Current Concepts in Ophthalmology Baltimore, MD

Committee on Energy and Commerce U.S. House of Representatives · Committee on Energy and Commerce U.S. House of Representatives Witness Disclosure Requirement - "Truth in Testimony"

Documents